VJHemOnc Podcast: Recent Episodes
VJHemOnc
The Video Journal of Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com
In this episode of the VJHemOnc podcast, we explore clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - conditions increasingly recognized as early indicators of myelodysplastic syndromes and acute myeloid leukemia.
Joining the discussion are leading experts George Vassiliou, MBBS, PhD, The University of Cambridge, Cambridge, UK, Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Mrinal Patnaik, MBBS, Mayo Clinic, Rochester, MN, Susan Slager, PhD, Mayo Clinic, Rochester, MN, and Anton Langerak, PhD, Erasmus MC, Rotterdam, The Netherlands. Together, they delve into recent advances in our understanding of CHIP and CCUS, touch on monoclonal B-cell lymphocytosis as another precursor condition, and share their insights on the potential value of early intervention in these pre-malignant states.
In this episode of the VJHemOnc podcast, we are joined by Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, a leading expert in the field, to discuss the complexities surrounding the diagnosis of amyloidosis, including both the light chain and ATTR subtypes.
The conversation covers early clinical signs that clinicians often overlook, key differences in presentation between subtypes, recommendations for initial diagnostic work-up, and the barriers that often delay timely diagnosis.
VJHemOnc was the official media partner for the recent 2nd International PNH Interest Group (IPIG) Conference held in Paris, France. In today’s podcast episode, you will hear some highlights from the event from leading experts in the field of paroxysmal nocturnal hemoglobinuria (PNH).
First, Jens Panse, MD, Aachen University Hospital, Aachen, Germany, Richard Kelly, MBChB, PhD, St James’s University Hospital, Leeds, UK, and Benjamin Chin-Yee, MD, MA, FRCPC, Western University, London, Canada, provide insight into challenging situations in the current era of PNH treatment, including switching from anti-C5 to proximal complement inhibition, discontinuing anticoagulation, and the management of pregnant patients with PNH. Following this, Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, King’s College Hospital NHS Foundation Trust, London, UK, discusses the role of ravulizumab in this disease, and Dr Kelly and Catherine Flynn, MD, St James’s Hospital, Dublin, Ireland, outline findings from the COMMODORE 1 and 2 trials. Finally, Jeff Szer, MBBS, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, comments on the clinical problem of thrombosis in patients with PNH, highlighting how this complication can be prevented.
In this episode of the VJHemOnc podcast, join us for an insightful conversation with Dr Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Dr Collins discusses the significant shifts in treatment approaches for patients with advanced-stage classical Hodgkin lymphoma over the past decade. He also explores the excitement around newer regimens, including nivolumab-AVD, BV-AVD, and more. To conclude, Dr Collins shares his approach to treating patients with relapsed disease, drawing focus on the role of autologous stem cell transplantation.
In this episode of the VJHemOnc podcast you will hear from Akshay Sharma, MBBS, MSc, St. Jude Children’s Research Hospital, Memphis, TN, who takes a deep dive into gene therapy for the treatment of sickle cell disease (SCD). Dr Sharma begins by discussing the status of gene therapy in SCD, outlining considerations for clinicians when selecting patients for these therapies, and commenting on the risk of infection. He then touches on the role of palliative care in patients with SCD undergoing gene therapy or transplantation, and provides his view on the benefits and challenges of gene therapy in this non-malignant hematological disorder. Finally, you will hear Dr Sharma's valuable insight into the risk of leukemia after lentiviral gene therapy.
Today's VJHemOnc podcast features discussions from the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025, which was held recently in Miami, FL. First you will hear from Elizabeth Budde, MD, PhD, City of Hope, Duarte, CA, Mohammad Rashidian, PhD, Dana-Farber Cancer Institute, Boston, MA, Michael Jain, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, and Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, who explore outcomes of treatment with CAR T-cells and potential strategies to enhance their efficacy and minimize toxicities.
Michael Hudecek, MD, University of Würzburg, Würzburg, Germany, then provides insight into his keynote talk on accelerating CAR T-cell therapeutics with small molecules and CRISPR 2.0 gene editing. This is followed by Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, Tara Graff, DO, MS, Mission Cancer and Blood, Des Moines, IA, and Caron Jacobson, MD, Dana-Farber Cancer Institute, Boston, MA, who share their perspectives on how to improve access and delivery of T-cell engaging therapies in the community.
This episode features leading experts Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, and Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, who provide key insights into the management of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), guided by the latest ESMO clinical practice recommendations. They explore treatment strategies at first relapse and for double-refractory patients, including fixed-duration combinations and the emerging role of the non-covalent BTK inhibitor, pirtobrutinib. Additionally, the experts share their perspectives on the role of allogeneic stem cell transplantation and CAR T-cell therapy, and offer a glimpse into promising therapies on the horizon, such as BTK degraders and bispecific antibodies.
VJHemOnc was delighted to be media partners for the 18th International Workshop on Multiple Myeloma (iwMyeloma), held in Miami, FL. This podcast episode features highlights from the meeting.
First, you will hear from Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Thomas Martin, MD, University of California San Francisco, San Francisco, CA, and Adriana Rossi, MD, Mount Sinai, New York City, NY, who share updates with the use of several agents in multiple myeloma. Damian Green, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, and Rachid Baz, MD, Moffitt Cancer Center, Tampa, FL, will then discuss practical considerations when using T-cell therapies, including managing adverse events and improving access.
In this VJHemOnc podcast, experts Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, Lydia Scarfò, MD, Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan, Italy, and Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, provide insights into the latest updates to the ESMO clinical practice guidelines for chronic lymphocytic leukemia (CLL). They cover key topics such as diagnostic advancements, frontline treatment strategies based on IGHV mutational status, the role of double oral combinations, the importance of measurable residual disease (MRD)-guided treatment, and the debate between time-limited and continuous regimens.
In this week’s VJHemOnc podcast, we’ll be sharing highlights from the 51st Annual Meeting of the EBMT, with a focus on the prevention and management of graft-versus-host disease (GvHD) and infections associated with stem cell transplantation (SCT). You will also hear about the potential of artificial intelligence (AI) in hematology and transplantation.
Tune in as experts Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, and Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, provide insights into current treatment approaches for acute and chronic GvHD, discussing the advent of new therapies. Following this, you’ll hear about cytomegalovirus (CMV) management from Per Ljungman, MD, PhD, Karolinska Institute, Stockholm, Sweden, and human herpesvirus 6 (HHV-6) diagnosis from Eleftheria Kampouri, MD, University of Lausanne, Lausanne, Switzerland, and Raffaella Greco, MD, PhD, San Raffaele Hospital, Milan, Italy.
Finally, Manuela Spadea, MD, University of Turin, Turin, Italy, comments on ushering in the era of the hematologist-AI alliance, and Adrián Mosquera-Orgueira, MD, PhD, Santiago Clinic Hospital CHUS, Santiago, Spain, highlights the potential for harnessing machine learning to predict post-SCT outcomes in patients with myelofibrosis (MF).
This podcast episode features experts Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, who discuss the sequencing of therapies in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). They focus on the sequencing of CAR T-cells and bispecific antibodies in diffuse large B-cell lymphoma (DLBCL), the use of BTK inhibitors (BTKis) in mantle cell lymphoma (MCL), and advances in the treatment of follicular lymphoma.
CAR T-cell therapy has revolutionized the lymphoma treatment landscape in recent years. In this episode, we delve into cutting-edge CAR strategies being investigated for lymphoma, including allogeneic products, trispecific CARs, and more. Key highlights include insights into CTX112, a next-generation allogeneic CRISPR-Cas9 engineered CD19 CAR T-cell product. This episode also covers studies of trispecific CAR T-cells targeting CD19, CD20, and CD22.
Stay tuned to learn more about these promising approaches from experts Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, Armin Ghobadi, MD, Washington University School of Medicine, St. Louis, MO, Evandro Bezerra, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, and Valentín Ortiz-Maldonado, MD, Hospital Clinic Barcelona, Barcelona, Spain.
Newly diagnosed acute myeloid leukemia (AML) is traditionally treated with intensive chemotherapy for eligible patients, but ongoing research is exploring the addition of targeted agents. This podcast focuses on approaches being explored to optimize induction therapy in AML, featuring experts Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, Ioannis Mantzaris, MD, Montefiore Medical Center/Albert Einstein College of Medicine, New York City, NY, Selina Luger, MD, FRCPC, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, Harry Erba, MD, PhD, Duke University, Durham, NC, Fabio Guolo, MD, University of Genoa, Genoa, Italy, and David Sallman, MD, Moffitt Cancer Center, Tampa, FL.
The experts discuss key trials in this space, including venetoclax combined with intensive induction chemotherapy, a Phase II study comparing midostaurin with gilteritinib in FLT3-mutated AML (NCT03836209), and the combination of ziftomenib with intensive chemotherapy. They also examine the role of CPX-351 in induction therapy and its potential combination with gemtuzumab ozogamicin.
BTK inhibitors have transformed the treatment landscape in both frontline and relapsed/refractory (R/R) mantle cell lymphoma (MCL), offering a targeted therapy option for patients.
In this podcast, you will hear from Krish Patel, MD, Sarah Cannon Cancer Institute, Nashville, TN, Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE, Adrian Minson, MBBS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, and David Lewis, MD, Plymouth University, Plymouth, UK. The experts cover a variety of topics, exploring the role of BTK inhibitors in R/R MCL, promising combinations being explored, and strategies to overcome resistance.
In recognition of Myeloma Awareness Month 2025, this podcast explores key unmet needs and unanswered questions in myeloma research and patient care, offering insights and strategies for healthcare professionals to address them. The discussion centers on four topics: the treatment of smoldering myeloma, managing frail and elderly patients, challenges in triple-class refractory disease, and racial disparities in myeloma care.
Featuring experts Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Tarek Mouhieddine, MD, Mount Sinai Medical Center, New York City, NY, Mateo Mejia Saldarriaga, MD, Weill Cornell Medicine, New York, NY, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, Joseph Mikhael, MD, MeD, FRCPC, FACP, Translational Genomics Research Institute (TGen), Phoenix, AZ, & International Myeloma Foundation, Studio City, CA, Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center & University of Miami, Miami, FL, P. Joy Ho, MBBS, DPhil, FRACP, FRCPA, FFSc(RCPA), Royal Prince Alfred Hospital & University of Sydney, Sydney, Australia, Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, and Joselle Cook, MBBS, Mayo Clinic, Rochester, MN.
CAR T-cell therapy has become an established treatment for several hematological malignancies, including acute lymphoblastic leukemia (ALL), and has significantly changed the therapeutic landscape for patients. In this podcast episode, renowned experts will share insight into the use of CAR-T in ALL, including updates of pivotal trials, novel approaches being explored, and real-world outcomes.
First, you will hear from Valentín Ortiz-Maldonado, MD, Hospital Clinic Barcelona, Barcelona, Spain, who shares the results of the pivotal CART19-BE-02 trial (NCT04778579), a multicenter study investigating varnimcabtagene autoleucel (var-cel) in adult patients with relapsed/refractory (R/R) B-cell ALL (B-ALL). Following this, Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, and Jae Park, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provide valuable insight into findings from the FELIX trial (NCT04404660), the results of which led to the FDA approval of obecabtagene autoleucel (obe-cel) for adult patients with R/R B-ALL in November 2024. Next, Ibrahim Muhsen, MD, Baylor University Medical Center, Dallas, TX, shares the findings of a retrospective analysis evaluating the efficacy and safety of brexucabtagene autoleucel (brexu-cel) in older patients with R/R B-ALL. Finally, you will hear some updates of trials assessing novel CAR-T approaches in ALL from Armin Ghobadi, MD, Washington University School of Medicine, St. Louis, MO, and Evandro Bezerra, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Today's podcast features a discussion with experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, from the 66th ASH Annual Meeting and Exposition. They share their key highlights in amyloidosis from the meeting, including updates from the ANDROMEDA trial (NCT03201965), the risk stratification of patients with light chain (AL) amyloidosis, the value of measurable residual disease (MRD), and potential advances with CAR T-cell therapy in this disease setting.
This episode of the VJHemOnc podcast covers updates in non-malignant hematological diseases from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. You will hear the latest updates in sickle cell disease (SCD), thalassemia, and hemophilia from leading experts.
First, Sophia Delicou, MD, Hippokration General Hospital, Athens, Greece, will provide an update on the HIBISCUS (NCT04624659) trial of etavopivat in SCD, and Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, will present updated results of the RUBY (NCT04853576) trial investigating reni-cel in severe SCD. This will be followed by an update of a trial being conducted in patients with transfusion-dependent thalassemia, the ENERGIZE-T study (NCT04770779), from Maria Domenica Cappellini, MD, University of Milan, Milan, Italy. Finally, you will hear the results of the explorer7 trial (NCT04083781) in hemophilia A and B from Amy Shapiro, MD, Indiana University Hemophilia Center, Indianapolis, IN.
The post Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia appeared first on VJHemOnc.
This podcast brings you exclusive updates on multiple myeloma from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, CA. In this episode, experts Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York, NY, Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, Mansi Shah, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center & University of Miami, Miami, FL, and Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, share key insights from the meeting.
The discussion covers updates on smoldering myeloma, including the practice-changing results of the AQUILA (NCT03301220) study, as well as the latest advances in bispecific antibodies for relapsed/refractory multiple myeloma. The experts also highlight exciting research to watch for in 2025. Finally, they provide guidance on the use of measurable residual disease (MRD) and address the ongoing challenge of treating high-risk multiple myeloma.
The post Post-ASH myeloma highlights: key takeaways for community physicians & trials to look out for in 2025 appeared first on VJHemOnc.
In this podcast, we bring you exclusive updates in acute myeloid leukemia (AML) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA.
You will hear insights into novel approaches to frontline chemotherapy and BCL2 inhibition from experts Ioannis Mantzaris, MD, Montefiore Medical Center/Albert Einstein College of Medicine, New York City, NY, Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Chong Chyn Chua, MBBS, FRACP, FRCPA, The Alfred Hospital and Monash University, Melbourne, Australia.
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, Emma Searle, MBChB, MA, MRCP, FRCPath, PhD, The Christie NHS Foundation Trust, Manchester, UK, Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, and Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, will then go on to share updates on the use of menin inhibitors in relapsed/refractory AML.
This will be followed by Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, and Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, who discuss the management of FLT3-ITD+ AML.
The post Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML appeared first on VJHemOnc.
This podcast episode covers highlights in myeloproliferative neoplasms (MPNs) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA.
First, you will hear key trial updates in myelofibrosis (MF) from Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Francesco Passamonti, MD, University of Milan, Milan, Italy. Following this, Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, will present initial results from the Phase I/II SANRECO trial (NCT05499013) evaluating divesiran in patients with polycythemia vera (PV). Firas El Chaer, MD, University of Virginia, Charlottesville, VA, and Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, will then give updates on trials exploring novel approaches for patients with relapsed/refractory (R/R) myelofibrosis. Finally, you will hear an update on the BOREAS trial (NCT03662126) from Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX.
The post Post-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more! appeared first on VJHemOnc.
Today’s podcast showcases key updates in non-Hodgkin lymphoma (NHL) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA.
First, you will hear from Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, Catherine Diefenbach, MD, NYU Langone, New York, NY, and Jia Ruan, MD, PhD, Weill Cornell Medical College, New York City, NY, who discuss novel combinations being explored in the frontline setting for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Sattva Neelapu, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, will then give updates on the use of CAR T-cells in the relapsed/refractory (R/R) setting for NHL, including follicular lymphoma (FL) and DLBCL. This will be followed by Catherine Diefenbach, MD, NYU Langone, New York, NY, and Taylor Brooks, MD, Cleveland Clinic, Cleveland, OH, who discuss the use of bispecific antibodies, and Julio Chavez, MD, Moffitt Cancer Center, Tampa, FL, who shares data on CELMoDs under investigation for the treatment of FL and DLBCL.
The post Post-ASH NHL highlights: novel combinations in the frontline setting and advancements with immunotherapy in the R/R setting appeared first on VJHemOnc.
This podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. This episode focuses on updates in myelodysplastic syndromes (MDS).
You will hear insights into managing anemia in lower-risk MDS (LR-MDS) from Sophie Park, MD, CHU Grenoble Alpes, Grenoble, France, Esther Oliva, MD, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, and Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany. They share data from the EPO-Pretar trial (NCT03223961), which is investigating early versus late onset of epoetin alfa treatment, an analysis of patient-reported outcomes in the COMMANDS trial (NCT03682536), and the effect of prior therapies on the activity of imetelstat in the IMerge trial (NCT02598661).
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, and Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, then go on to discuss novel approaches to managing higher-risk MDS (HR-MDS), including an individualized allogeneic stem cell transplantation (alloSCT) approach and novel non-transplant treatment approaches.
The post Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS appeared first on VJHemOnc.
VJHemOnc recently attended the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, where we gained expert insights into cutting-edge research in hematological malignancies. This podcast series will cover highlights in a variety of disease areas. Today’s episode focuses on chronic lymphocytic leukemia (CLL).
You will hear from experts Jeff Sharman, MD, Willamette Valley Cancer Institute, Eugene, OR, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, and Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia. They discuss key updates on the use of BTK inhibitors in CLL, including the BRUIN CLL-321 (NCT04666038) and AMPLIFY (NCT03836261) trials, as well as the BTK degraders NX-2127 and NX-5948. They then go on to speak about novel approaches being explored, including treatment with the bispecific antibody epcoritamab in the EPCORE-CLL1 (NCT04623541) trial, and the use of sonrotoclax in the BGB-11417-101 (NCT04277637) trial.
The post Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more! appeared first on VJHemOnc.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by involvement of the skin, bone marrow, and lymph nodes, often associated with a poor prognosis. In this podcast episode, Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an in-depth exploration of BPDCN. Dr Pemmaraju discusses the challenges in treating this disease and reviews current therapeutic options such as chemotherapy, tagraxofusp, and transplantation. He takes a deep dive into the CD123-targeted agent tagraxofusp, addressing patient eligibility, the role of tagraxofusp in bridging to transplantation, and real-world data on its use. Additionally, Dr Pemmaraju shares insights into ongoing clinical trials and emerging treatments for BPDCN, including novel CD123-targeted therapies, combination strategies, BCL2 inhibitors, and immunotherapeutic approaches.
The post Advancing treatment for BPDCN: current therapies, a deep dive into tagraxofusp, & emerging novel agents appeared first on VJHemOnc.
This week’s podcast focuses on strategies to improve care for patients with sickle cell disease (SCD), featuring expert insights from the 19th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT 2024), which was held in London, UK. You will hear from Natasha Archer, MD, MPH, Harvard Medical School, Boston, MA, Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Trust, London, UK, Christiana Dinah, BSc, MBBS, MRes, London North West Healthcare NHS Trust, Harrow, UK, Leon Tshilolo, MD, PhD, Centre Hospitalier Monkole, Kinshasa, DR Congo, and Marsha Treadwell, PhD, University Of California San Francisco, San Francisco, CA. They speak about pain management in SCD, ongoing projects including the Universal Care Plan Project and the Sickle Eye Project, and unmet needs in Sub-Saharan Africa and from a psychosocial perspective.
The post Improving care for patients with SCD: pain management, ongoing projects & unmet needs appeared first on VJHemOnc.
In this podcast, experts Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, Nicole LeBoeuf, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, and Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, share insights into the clinical presentation, diagnosis, and treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematological malignancy. Dr Luskin and Dr Shimony provide insights from a hematology standpoint, while Dr LeBoeuf explores the diagnosis and pathogenesis of this rare disease through a dermatology perspective. The discussion covers pathology, patient demographics, the use of tagraxofusp and venetoclax, and the importance of collaboration within multidisciplinary teams.
The post Understanding BPDCN: dermatology and hematology perspectives on presentation, diagnosis, treatment, & multidisciplinary care appeared first on VJHemOnc.
Today’s podcast episode focuses on the management of complications associated with Waldenström’s macroglobulinemia (WM), featuring expert insights from the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) held in Prague, Czech Republic. You will hear from Shirley D’Sa, MD, FRCP, FRCPath, University College London, London, UK, Monique Minnema, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands, and Jithma Abeykoon, MD, Mayo Clinic, Rochester, MN, who share advice on managing IgM demyelinating neuropathy, Bing-Neel syndrome, and acquired von Willebrand disease, respectively. Finally, Adam Sperling, MD, PhD, Dana Farber Cancer Institute, Boston, MA, speaks about clonal hematopoiesis in WM, giving advice on how to detect it and how it may impact treatment strategies.
The post Managing complications associated with WM: Bing-Neel syndrome, acquired von Willebrand disease, & more! appeared first on VJHemOnc.
This week’s podcast features discussions on the use of immunotherapy in the treatment of high-risk multiple myeloma (HRMM) from the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM), which took place Charleston, SC. You will hear from experts Ajai Chari, MD, University of California San Francisco, San Francisco, CA, and Krina Patel, MD, MSc, The University of Texas MD Anderson Cancer Center, Houston, TX, who discuss the use of CAR T-cells in the treatment of HRMM. They highlight clinical trial findings, the use of CAR-Ts in specific high-risk subgroups, and the potential for allogeneic CAR T-cell products. Additionally, Thomas Martin, MD, University of California San Francisco, San Francisco, CA, Ajai Chari, MD, University of California San Francisco, San Francisco, CA, Niels Van de Donk, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, and Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, speak about bispecific antibodies in HRMM. They discuss strategies to optimize treatment, potential resistance mechanisms, and combination strategies.
The post CAR-T therapies and bispecific antibodies in the treatment of high-risk multiple myeloma: updates from iwHRMM 2024 appeared first on VJHemOnc.
This podcast features a discussion from the 6th International Workshop on Acute Leukemias (iwAL) 2024, which took place in Phoenix, AZ. You will hear from Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, Guillermo Montalban-Bravo, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Emma Groarke, MD, National Institutes of Health, Bethesda, MD, who discuss several rare myeloid diseases, including accelerated- and blast-phase myeloproliferative neoplasms (MPN-AP/BP), blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML), and VEXAS syndrome. The experts provide valuable insight into the treatment of these diseases and the unique challenges associated with each one.
The post The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS appeared first on VJHemOnc.
Today’s podcast focuses on the role of BTK inhibitors (BTKis) in the treatment of mantle cell lymphoma (MCL). You will hear from experts Krish Patel, MD, Providence Swedish Cancer Institute, Seattle, WA, Marek Trněný, MD, PhD, Charles University Hospital, Prague, Czech Republic, Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Craig Portell, MD, University of Virginia, Charlottesville, VA. They share updates on trials investigating BTKis in the frontline treatment of MCL, including the ECHO (NCT02972840), SHINE (NCT01776840), and TRIANGLE (NCT02858258) studies. They then go on to discuss how these agents are optimally sequenced and give advice for managing cardiac toxicities associated with BTKis.
The post Exploring the role of BTK inhibitors in mantle cell lymphoma: sequencing & managing adverse events appeared first on VJHemOnc.
Menin inhibitors are emerging as a promising therapeutic approach in acute myeloid leukemia (AML), particularly in patients with specific genetic mutations such as KMT2A-rearranged and NPM1-mutated AML. These inhibitors disrupt the leukemogenic signaling pathways that drive leukemia cell proliferation by blocking the actions of menin. They can help restore regular gene expression and halt the progression of AML.
In this podcast episode, you will hear updates on menin inhibitors in AML from the 6th International Workshop on Acute Leukemias (iwAL), which took place in Phoenix, AZ. Experts Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, and Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, delve into current data on the four menin inhibitors being investigated in AML. They then go on to discuss the development of resistance to this drug class and the potential value of these agents in the post-transplant setting
The post An update on menin inhibition in AML from iwAL 2024: current data, mechanisms of resistance, & more! appeared first on VJHemOnc.
Today’s podcast features discussions from the 21st International Workshop on Non-Hodgkin Lymphoma (iwNHL) which took place in Nice, France. You will hear updates on the use of CAR T-cell therapy in non-Hodgkin lymphoma (NHL) from experts Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children’s National Health System, Washington, DC, Stephen Schuster, MD, University of Pennsylvania, Philadelphia, PA, and Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX. They discuss where CAR-T fits into the treatment landscape, managing toxicities, and the potential of allogeneic CAR-T products.
You will also hear from Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, and Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, who share insights into the use of bispecific antibodies in the treatment of NHL. Their discussion focuses on comparisons between CAR-T and bispecifics and the unique challenges of using bispecific antibodies, including mitigating toxicities. They also mention exciting combination approaches with antibody-drug conjugates and co-stimulatory agents.
The post CAR T-cells and bispecific antibodies in the treatment of NHL: updates from iwNHL 2024 appeared first on VJHemOnc.
Today’s podcast features a discussion with leading experts Harry Erba, MD, PhD, Duke University, Durham, NC, Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, on strategies to prolong remission in acute myeloid leukemia (AML). They focus on the roles of intensive chemotherapy, allogeneic stem cell transplantation, and maintenance therapies. Key topics include optimizing initial therapy to achieve deeper remissions, the benefits of using measurable residual disease (MRD) assays to tailor post-remission treatments, and exploring new maintenance options such as targeted agents.
The post Prolonging remission in AML: current approaches & future outlooks appeared first on VJHemOnc.
Welcome to the final episode of VJHemOnc’s Blood Cancer Awareness Month special series!
This episode focuses on the role of artificial intelligence (AI) in personalizing blood cancer care. Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses the value of AI in hematological oncology and how it is currently used in the clinic. He then shares details of a treatment infection model for chronic lymphocytic leukemia (CLL) that has been deployed in his institution. Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York City, NY, delves into the role of AI in the classification of multiple myeloma and the prediction of patients who will need transplantation. He also touches on the use of AI to better understand genomic data.
References
Agius R, Riis-Jensen A. C, Wimmer B, et al. Deployment and validation of the CLL treatment infection model adjoined to an EHR system. NPJ Digit Med. 2024;7(1):147.
Niemann C, Levin M-D, Österborg A, et al. The CLL Treatment Infection Model – Clinical Prospective Validation as Part of the Prevent-Acall Trial. Hemasphere. 2023;7(Suppl):e1432517.
The post A focus on the use of artificial intelligence to personalize blood cancer care appeared first on VJHemOnc.
Welcome to the third episode of VJHemOnc’s Blood Cancer Awareness Month special series!
The focus of this episode is pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). You will hear from Michele Redell, MD, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX, who shares insights into the Pediatric Acute Leukemia (PedAL) Screening Trial and challenges that remain in the treatment of AML. Mark Litzow, MD, Mayo Clinic, Rochester, MN, discusses a study investigating drug responses in children compared to adults. Finally, Christina Peters, MD, St. Anna Children’s Hospital, Vienna, Austria, speaks on the FORUM trial (NCT01949129) and CAR-T therapy for pediatric patients.
The post A focus on pediatric leukemias: trials, treatments, & challenges appeared first on VJHemOnc.
Welcome to the second episode of VJHemOnc’s Blood Cancer Awareness Month special series!
Today’s episode focuses on the psychosocial impacts of living with blood cancer. First, you will hear from Lorna Warwick, BA, Lymphoma Coalition, Toronto, Canada, who shares the work of the Lymphoma Coalition Global Patient Survey. Next, you will hear insights from Surabhi Chaturvedi, MBACP, King’s College Hospital NHS Foundation Trust, London, UK, who is a senior psychotherapist in hematological oncology. Finally, Charlie Craddock, CBE, FRCP, FRCPath, University of Birmingham, Birmingham, UK, will discuss the psychosocial impacts of transplantation in acute myeloid leukemia (AML).
The post A focus on the psychosocial impacts of living with blood cancer appeared first on VJHemOnc.
Welcome to the first episode of VJHemOnc’s Blood Cancer Awareness Month special series!
This episode focuses on global perspectives of blood cancers and addresses the disparities that exist in awareness, diagnosis, and treatment. First, Lalit Kumar, MD, MBBS, Artemis Hospital, New Delhi, India, discusses challenges that exist in the management of blood cancers in India, and programs that are in place to address these. Joseph Mikhael, MD, MEd, FRCPC, FACP, Translational Genomics Research Institute (TGen), Phoenix, AZ, then goes on to address racial disparities in the treatment of multiple myeloma in America. Amrutha Sridhar, MBBS, University College London Hospitals, London, UK, discusses socioeconomic and racial disparities in myeloma trial recruitment, followed by Brian Koffman, MDCM (retired), MS Ed, CLL Society, Inc., Chula Vista, CA, who shares insights into a survey investigating global disparities in access to treatment and resources for patients with chronic lymphocytic leukemia in low-income countries.
The post Global perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatment appeared first on VJHemOnc.
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs) characterized by the overproduction of red blood cells and platelets, respectively, due to mutations in hematopoietic stem cells.
This podcast features a discussion from the 2nd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPNs). Experts Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL; Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; and Kristen Pettit, MD, University of Michigan, Ann Arbor, MI, share insights into the management of PV and ET. They focus on treating the adolescent and young adult (AYA) population, defining goals when treating patients, and the feasibility of assessing long-term outcomes in clinical trials. Additionally, they emphasize collaborative research approaches and explore the potential for early interventions at the stage of clonal hematopoiesis in AYA patients.
The post Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more appeared first on VJHemOnc.
This week’s VJHemOnc podcast brings you updates in hemophilia from the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually.
You hear from experts Omolade Awodu, MBChB, MD, FMCPath, University of Benin, Benin City, Nigeria, who discusses key hemophilia clinical trials in 2024, Radek Kaczmarek, PhD, Indiana University School of Medicine, Indianapolis, IN, who gives an overview of gene therapies for hemophilia, and Matteo Luciani, MD, Bambino Gesù Children’s Hospital, Rome, Italy, who shares insights into the remaining challenges for patients with hemophilia.
The post Hemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challenges appeared first on VJHemOnc.
In myelodysplastic syndromes (MDS), chronic inflammation driven by the innate immune system plays a key role in disease progression. Signal Transducer and Activator of Transcription (STAT) and Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) are critical mediators in this process, where dysregulated signaling leads to aberrant hematopoiesis and the promotion of a pro-inflammatory environment that supports the clonal expansion of malignant cells.
This podcast episode features experts Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, Aditi Shastri, MD, Montefiore Medical Center, Bronx, NY, Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, and Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT. They discuss the role of inflammation and immune interventions from the 2nd International Workshop on Myelodysplastic Syndromes and Myeloproliferative Neoplasms (iwMDS) 2024, held in Boston, MA. They focus on the targeting of STAT and IRAK4, the pivotal Phase III STIMULUS-MDS2 trial (NCT04266301) of sabatolimab, and lessons that can be learned from clinical trial failures.
The post Inflammation and immune interventions in MDS: targeting STAT, IRAK4, & more appeared first on VJHemOnc.
Today’s VJHemOnc podcast features experts Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Foundation Trust, London, UK, and Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon. They discuss key updates in sickle cell disease (SCD) and thalassemia from the 29th Congress of the European Hematology Association (EHA), held in Madrid, Spain.
The experts share key trial updates, including the Phase I/II RUBY trial (NCT04853576) of renizgamglogene autogedtemcel (reni-cel) for SCD, and the Phase III ENERGIZE trial (NCT04770779), investigating the safety and efficacy of mitapivat in non-transfusion-dependent (NTD) alpha- or beta-thalassemia. They also speak on unmet needs and challenges with gene therapies for these patients.
The post Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs appeared first on VJHemOnc.
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis, extramedullary hematopoiesis, and splenomegaly, often resulting in anemia and thrombocytopenia. There are many unmet treatment needs that remain in this space.
This week’s podcast features a discussion from the International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS 2024) held in Boston, MA. You will hear from Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Abdulraheem Yacoub, MD, The University of Kansas, Westwood, KS, Aaron Gerds, MD, MS, Cleveland Clinic, Cleveland, OH, and Claire Harrison, MD, FRCP, FRCPath, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, who discuss unmet treatment needs in MF. They focus on the management of prefibrotic MF and thrombocytopenia, novel agents beyond the JAK/STAT pathway, and endpoints for clinical trials.
The post Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials appeared first on VJHemOnc.
The introduction of Bruton’s tyrosine kinase (BTK) inhibitors into the treatment landscape for mantle cell lymphoma (MCL) has transformed the field and provided patients with a promising therapeutic option. In this podcast, you will hear from leading experts who discuss the value of these agents in MCL, sharing updates from EHA 2024.
Tune in as Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, Tycel Phillips, MD, City of Hope, Duarte, CA, Chan Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, and Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, share insights into the impact of BTK inhibitors on patient outcomes, the nuances between covalent and non-covalent BTK inhibitors, and further discuss ongoing trials evaluating these agents.
The post The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024 appeared first on VJHemOnc.
In today’s VJHemOnc podcast, we will be sharing novel developments in lower-risk myelodysplastic syndromes (LR-MDS) and important practical considerations when treating patients.
You will hear from experts Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA. They discuss important considerations for physicians when treating LR-MDS, providing valuable insights into some of the common pitfalls in clinical practice which may lead to suboptimal responses in patients.
The post Novel developments in lower-risk MDS & important practical considerations when treating patients appeared first on VJHemOnc.
BCMA-targeting bispecific antibodies treat multiple myeloma by binding to BCMA on malignant plasma cells and directing T-cells to initiate target cell killing. This podcast will provide updates on the use of BCMA-targeting bispecific antibodies in relapsed/refractory (R/R) multiple myeloma from the 2024 American Society of Clinical Oncology (ASCO) Meeting and the 29th Congress of the European Hematology Association (EHA).
You will hear from Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, who will discuss updated data from the MagnetisMM-3 trial (NCT04649359) of elranatamab and real-world findings from a French compassionate use program using this agent. Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, will provide insights into the real-world step-up dosing of teclistamab to mitigate toxicities. Finally, Sundar Jagannath, MD, Tisch Cancer Institute at Mount Sinai, New York, NY, will discuss a matched adjusted indirect comparison (MAIC) of the novel bispecific linvoseltamab with teclistamab, and the sequencing of bispecific antibodies with CAR T-cells.
The post Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024 appeared first on VJHemOnc.
In today’s VJHemOnc podcast, we will be sharing key updates in the treatment of chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT) from the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
You will hear from experts Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, who will discuss combinations of BTK and BCL2 inhibitors, the efficacy of BTK degraders in CLL, and the role of epcoritamab in the treatment of RT.
The post Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more appeared first on VJHemOnc.
Welcome to today’s VJHemOnc podcast episode, where we will be sharing key highlights from the 2024 International Symposium on Amyloidosis (ISA), which was held in Rochester, MN. This podcast covers a variety of unmet needs in light chain (AL) amyloidosis, as well as emerging trials in the field.
Join leading experts Mario Nuvolone, MD, PhD, University of Pavia, Pavia, Italy, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, Patrick Hagen, MD, Loyola University Medical Center, Chicago, IL, and Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, as they discuss the critical importance of early diagnosis in AL amyloidosis, exciting clinical trials in progress, patient selection for stem cell transplantation (SCT), and more.
The post Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT appeared first on VJHemOnc.
While there have been advances in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) in recent years, one major challenge that remains is the treatment of patients following the failure of erythropoiesis-stimulating agents (ESAs).
In this podcast, experts Amer Zeidan, MBBS, Yale Cancer Center, New Haven, CT, Valeria Santini, MD, University of Florence, Florence, Italy, and Courtney DiNardo, MD, MSCE, The University of Texas MD Anderson Cancer Center, Houston, TX, delve into the historical context of treatment developments, sharing insights on the emergence of novel agents like luspatercept and imetelstat. They explore the current paradigm for managing LR-MDS, including the strategic use of hypomethylating agents (HMAs) and other innovative therapies. The experts also touch on the future of clinical trials and the importance of early intervention in improving quality of life (QoL) and survival for patients.
The post Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks appeared first on VJHemOnc.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cells, characterized by skin lesions and frequent involvement of bone marrow and lymphoid tissues. Patients have a poor prognosis, making early diagnosis and advanced treatments, including targeted therapies, crucial for improving outcomes.
In this podcast, Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, and Emanuele Angelucci, MD, Armando Businco Oncology Hospital, Sardegna, Italy, discuss the treatment and monitoring of BPDCN. They highlight the role of CD123-targeting agents, including tagraxofusp, the involvement of the central nervous system (CNS), and share strategies for treating adolescents and young adults (AYAs) with this aggressive disease.
The post BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients appeared first on VJHemOnc.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cells, characterized by skin lesions and frequent involvement of bone marrow and lymphoid tissues. Patients have a poor prognosis, making early diagnosis and advanced treatments, including targeted therapies, crucial for improving outcomes.
In this podcast, Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, and Emanuele Angelucci, MD, Armando Businco Oncology Hospital, Sardegna, Italy, discuss the treatment and monitoring of BPDCN. They highlight the role of CD123-targeting agents, including tagraxofusp, the involvement of the central nervous system (CNS), and share strategies for treating adolescents and young adults (AYAs) with this aggressive disease.
Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR T-cells are engineered to target specific antigens expressed on lymphoma cells, and bispecific antibodies simultaneously bind to both tumor cells and immune cells, enhancing the immune response against NHL.
This podcast features experts Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, who discusses the future of CAR-T therapy and the risk of secondary malignancies, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, who gives an overview of the currently approved CAR-T products and bispecific antibodies in large B-cell lymphoma, and the optimal sequencing of these agents.
The post The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies appeared first on VJHemOnc.
The 17th International Workshop on Multiple Myeloma (iwMyeloma 2024) was held recently in Miami, FL, and brought together experts from around the world to discuss the latest updates, challenges, and research in the field.
In this episode, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Suzanne Lentzsch, MD, PhD, Columbia University, New York, NY, Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, and Suzanne Trudel, MSc, MD, Princess Margaret Cancer Centre, Toronto, Canada, discuss the use of various agents in myeloma, including the suitability of bisphosphonates to treat bone disease, and updates with the use of isatuximab and belantamab mafodotin. The experts also share their thoughts on the benefits of using measurable residual disease (MRD) as a surrogate endpoint in clinical trials.
The post iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials appeared first on VJHemOnc.
Myelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia and splenomegaly. MF-related anemia can be challenging to manage, and strategies are being explored to improve outcomes for patients.
Today’s VJHemOnc podcast features experts Mary Frances McMullin, MD, Queen’s University, Belfast, UK, who discusses strategies to manage anemia in MF, and Claire Harrison, MD, FRCP, FRCPath, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, who gives a comprehensive overview of promising MPN clinical trials in the UK, and further discusses how to approach young patients with MPNs.
The post Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs appeared first on VJHemOnc.
Graft-versus-host disease (GvHD) is a common complication following allogeneic stem cell transplantation (alloSCT), which is typically classified as acute or chronic. In this week’s VJHemOnc podcast, we’ll be sharing key highlights from the 50th Annual Meeting of the EBMT, drawing focus on the biology and treatment of GvHD.
Tune in as experts Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, Ernst Holler, MD, University Hospital Regensburg, Regensburg, Germany, and Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, provide insights into current and emerging treatment approaches for acute and chronic GvHD, discussing the advent of new therapies. Following this, you’ll learn about the importance of the gut microbiome in the severity of GvHD and how this can be manipulated to improve patient outcomes.
The post Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome appeared first on VJHemOnc.
In recent years, there has been great emphasis placed on the importance of cardio-oncology, with both cardiologists and hematologists highlighting the value of collaboration between specialists when treating patients with hematological malignancies. Furthermore, the 2022 European Society of Cardiology (ESC) cardio-oncology guidelines aim to help healthcare professionals with the treatment and management of cancer therapy-related cardiovascular toxicities (CTR-CVT).
In this podcast, Daniel Lenihan, MD, FACC, Saint Francis Healthcare System, Cape Girardeau, MO, Raul Cordoba, MD, PhD, University Hospital Fundación Jiménez Díaz, Madrid, Spain, and Iskra Pusic, MD, MSCI, Washington University School of Medicine, St. Louis, MO, unravel the critical relevance of cardio-oncology, stressing the significance of multidisciplinary teams (MDTs) and the application of the ESC 2022 guidelines. Discussing their experiences from different healthcare institutions across the globe, the experts underscore the importance of cooperation between cardiologists and hematologists as they navigate difficult medical decisions for patients with specific complications.
The post The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs appeared first on VJHemOnc.
Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the possibility of early interception is a growing area of interest in the field.
In this week’s podcast, you will hear from Shaji Kumar, MD, Mayo Clinic, Rochester, MN, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, and Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, who discuss novel technologies being explored to risk stratify individuals with SMM and MGUS. Following this, Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, Kwee Yong, PhD, FRCP, FRCPath, University College London, London, UK, and Omar Nadeem, MD, Dana-Farber Cancer Institute, Boston, MA, discuss the possibility of early interception in SMM, highlighting ongoing trials in the field. This episode is part of our podcast series from the 2024 Intercepting Blood Cancers (IBC) Workshop, which was held in Lisbon, Portugal.
The post Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification appeared first on VJHemOnc.
Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) are considered precursor diseases to hematologic malignancies, indicating early stages of blood disorders that may progress to more serious conditions such as leukemia or myelodysplastic syndromes (MDS).
In this podcast, Uma Borate, MD, The Ohio State University, Columbus, OH, Kelly Bolton, MD, PhD, Washington University School of Medicine, St. Louis, MO, and Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, discuss knowledge gaps in the field, share insights from ongoing trials, and further emphasize the importance of multidisciplinary teamwork in managing CHIP and CCUS. This episode is part of our podcast series from the 2024 Intercepting Blood Cancers (IBC) Workshop, which was held in Lisbon, Portugal.
The post CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors appeared first on VJHemOnc.
Monoclonal B-cell lymphocytosis (MBL) is a condition characterized by the presence of an abnormal increase in B lymphocytes in the blood. MBL is considered a precursor condition to chronic lymphocytic leukemia (CLL); however, not all cases of MBL progress to CLL, and many individuals with MBL do not require treatment.
In this podcast, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, Andrew Rawstron, PhD, Leeds Teaching Hospitals NHS Trust, Leeds, UK, and Anton Langerak, MD, PhD, Erasmus Medical Center and University, Rotterdam, The Netherlands, discuss the biology, classification, and possible interventions for MBL. This discussion took place at the 2024 Intercepting Blood Cancers Workshop in Lisbon, Portugal.
The post Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception appeared first on VJHemOnc.
The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory (R/R) disease. There are currently two approved CAR-T cells in multiple myeloma: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), with ongoing studies exploring the possibility of bringing these agents into earlier lines of treatment.
In this podcast, Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, and Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discuss the significance of CAR-T therapy in myeloma, how to select patients for CAR-T therapy, the evolving role of autologous stem cell transplantation (autoSCT), and more.
The post The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT appeared first on VJHemOnc.
While there have been advances in the treatment and management of amyloidosis in recent years, diagnosis remains a challenge due to the highly varied presentation of this disease. As clinicians and researchers work to improve outcomes for patients, there is increasing importance being placed on the role of the multidisciplinary team in treating these patients.
In this podcast, you will hear from Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, and Daniel Lenihan, MD, FACC, Saint Francis Health System, Cape Girardeau, MO, who discuss the significant role of cardio-oncology in amyloidosis, currently available therapies, diagnostic approaches being explored, and more.
The post Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology appeared first on VJHemOnc.
Although CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed regarding the use of these agents. One ongoing challenge is the prevention and management of CAR-T-related toxicities, including immune effector cell-associated hematotoxicity (ICAHT), as well as how to improve affordability and access to these agents.
In this podcast, you will hear from Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, who discusses the importance of lymphodepletion in CAR-T therapy, Kai Rejeski, MD, Memorial Sloan Kettering Cancer Center, New York, NY, who updates us on ICAHT, and Gérard de Pouvourville, PhD, ESSEC Business School, Cergy, France, who shares his thoughts on the cost effectiveness of these agents.
The post Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy appeared first on VJHemOnc.
The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells and antibody-based therapies. Despite these advances, several challenges remain in the field. In today’s episode, you will hear the latest updates with the use of CAR-T therapy in ALL, as discussed by renowned experts during the EBMT-EHA 6th European CAR T-cell meeting.
In this podcast, André Baruchel, MD, PhD, Hospital Robert Debré AP-HP, Paris, France, Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, and Alex Rampotas, MD, University College London, London, UK, cover several topics, including challenges with administering CAR-T therapy in B- and T-ALL, the possibility of exploring dual-targeting of CD19 and CD22 to overcome resistance, considerations for managing patients with B-ALL prior to CAR-T therapy, and more.
The post Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks appeared first on VJHemOnc.
The treatment landscape of acute myeloid leukemia (AML) has transformed in recent years with the introduction of novel targeted agents, including FLT3 inhibitors, IDH inhibitors, and menin inhibitors. Menin inhibitors are currently being explored in several clinical trials, both as monotherapy and in combination with other agents.
In this podcast, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Ghayas Issa, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Ibrahim Aldoss, MD, City of Hope, Duarte, CA, and Aaron Goldberg, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, comment on the growing role of targeted agents in AML. The experts draw focus on the promise of menin inhibitors, highlighting findings from the AUGMENT-101 (NCT04065399) and KOMET-008 (NCT05735184) trials.
The post Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents appeared first on VJHemOnc.
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-MDS; HR-MDS). Treatment and management strategies vary for LR-MDS versus HR-MDS, and a number of challenges remain in the field.
In this podcast, you will hear from leading experts who discuss several topics in LR-MDS and HR-MDS. Rena Buckstein, MD, FRCPC, Sunnybrook Research Institute, Toronto, Canada, and Valeria Santini, MD, University of Florence, Florence, Italy, discuss challenges in LR-MDS, including red blood cell transfusion dependence and approaching patients who fail erythropoiesis‑stimulating agents (ESAs). You will also hear from Amer Zeidan, MBBS, Yale Cancer Center, New Haven, CT, Aditi Shastri, MD, Montefiore Medical Center, Bronx, NY, and David Sallman, MD, Moffitt Cancer Center, Tampa, FL, who discuss novel targets in HR-MDS, moving past hypomethylating agents (HMAs), and ongoing trials in the field.
The post Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023 appeared first on VJHemOnc.
In the last decade, the treatment landscape of thalassemia has been transformed with the introduction of novel therapies. With several agents being evaluated in clinical trials, the future looks promising for patients. Despite these advances, there are challenges and unmet needs which remain, and both clinicians and researchers are working to address these, with the goal of improving outcomes for patients.
In this podcast, you will hear from experts Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, and Kevin Kuo, MD, MSc, FRCPC, University Health Network, Toronto, Canada, who discuss recent updates in thalassemia presented at the 2023 ASH Annual Meeting. The experts cover several topics, including the promise of novel gene therapies, the BEYOND trial (NCT03342404), and more.
The post Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine appeared first on VJHemOnc.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several challenges remain in the diagnosis, treatment and management of this disease, with a lack of clinical trials in the field. However, clinicians and researchers are working to improve upon these unmet needs, with novel therapies being investigated.
In this podcast, you will hear from Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Nerses Ghahramanyan, MD, Yeolyan Hematology and Oncology Center, Yerevan, Armenia, Marco Herling, MD, University of Leipzig, Leipzig, Germany, and Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy, who discuss promising therapies emerging in the field, current challenges, and more.
The post Updates, challenges and novel agents being explored in BPDCN appeared first on VJHemOnc.
The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic options, with associated benefits and challenges. Several ongoing clinical trials in the field are investigating potential treatment approaches and addressing many unanswered questions.
In this podcast, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, and Benjamin Derman, MD, University of Chicago, Chicago, IL, discuss several interesting topics in myeloma, including the challenges associated with sequencing anti-BCMA therapies, the prognostic value of circulating tumor cells (CTCs), and the growing role of quadruplet therapies in myeloma, with updates in this space from the 2023 ASH Annual Meeting.
The post Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets appeared first on VJHemOnc.
In recent years, the treatment landscape of sickle cell disease (SCD) has been revolutionized with the introduction of novel agents, including recently approved gene therapies. There are several ongoing trials evaluating the safety of these agents in patients, with promising results being demonstrated.
In this podcast, leading experts Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, and Josu de la Fuente, PhD, FRCP, FRCPI, FRCPCH, FRCPath, Imperial College London, London, UK, discuss key updates in SCD presented at the 2023 ASH Annual Meeting and Exposition. The experts cover several topics, including the pathogenesis of SCD, novel agents being explored, and the growing role of gene therapies.
The post Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy appeared first on VJHemOnc.
In recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents. While diagnosis and risk stratification remain a challenge, clinicians and researchers are working to improve upon these. Furthermore, novel immunotherapies are being explored in the field, providing hope for patients.
In this podcast, you will hear from experts Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, and Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, who discuss the latest updates in the treatment and management of AL amyloidosis at the 65th ASH Annual Meeting and Exposition.
The post ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis appeared first on VJHemOnc.
The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed in recent years. Several clinical trials are exploring the safety and efficacy of novel agents and combinations, with promising advances being made.
At the 65th ASH Annual Meeting and Exposition, leading experts Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, and Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, shared their key highlights in MPNs, commenting on ongoing trials and promising combinations being explored, as well as future outlooks.
The post MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF appeared first on VJHemOnc.
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, and David Miklos, MD, PhD, Stanford University, Stanford, CA, discuss the growing role of CAR-T therapy in NHL and further comment on how to expand the CAR platform in this disease setting.
The post iwNHL 2023 Session V: Expanding the CAR platform in NHL appeared first on VJHemOnc.
The biennial International Workshop on Chronic Lymphocytic LeukemiaTM (iwCLL 2023) was held recently in Boston, MA, and brought together experts who shared the latest updates in the treatment and management of CLL.
Tune in as we share some key highlights from this year’s meeting. In this podcast, a variety of topics are covered, including the role of continuous BTK inhibitors (BTKis) in CLL, the importance of investigating the biology of Richter’s transformation (RT), and the need to address the underrepresentation of elderly patients in CLL clinical trials. You will hear from several leading experts, including Kerry Rogers, MD, Ohio State University, Columbus, OH, Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd, CLL Society, Inc., Chula Vista, CA, Raul Cordoba, MD, PhD, University Hospital Fundación Jiménez Díaz, Madrid, Spain, and Adam Kittai, MD, Ohio State University, Columbus, OH.
The post iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials appeared first on VJHemOnc.
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Tanya Siddiqi, MD, City of Hope, Duarte, CA, and Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discuss the role of BTK inhibitors and degraders in NHL. Following this, you will hear from Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, Marion Subklewe, MD, Ludwig-Maximilians University, Munich, Germany, Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, and Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, who discuss the growing role of bispecific antibodies, including glofitamab, epcoritamab and odronextamab, in this disease setting.
The post iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies appeared first on VJHemOnc.
In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in this disease. Early and accurate diagnosis present a key challenge, and both clinicians and researchers are investigating novel strategies with the aim of improving outcomes for patients.
In this podcast, Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN, Paolo Lopedote, MD, St Elizabeth’s Medical Center, Boston, MA, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Efstathios Kastritis, MD, University of Athens, Athens, Greece, discuss unmet needs in AL amyloidosis, as well as novel immunotherapy strategies being explored. The experts also highlight the prevalence of clonal hematopoiesis of indeterminate potential (CHIP) in this disease setting.
The post Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP appeared first on VJHemOnc.
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, John Gribben, MD, DSc, FRCPath, FRCP, FMedSci, Barts Cancer Institute, London, UK, Laurie Sehn, MD, University of British Columbia, Vancouver, Canada, Andrew Davies, MRCP, PhD, University of Southampton, Southampton, UK, and Sven De Vos, MD, PhD, David Geffen School of Medicine at UCLA, Los Angeles, CA, discuss novel therapies in NHL, drawing focus on the role of antibody-drug conjugates (ADCs).
The post iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL appeared first on VJHemOnc.
The treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years, although several challenges remain. There are ongoing clinical trials investigating the safety and efficacy of novel agents for this group of diseases, as well as strategies to improve the diagnosis and risk stratification of patients.
In this podcast, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Anthony Hunter, MD, Winship Cancer Institute of Emory University, Atlanta, GA, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, and John Mascarenhas, MD, Mount Sinai Medical Center, New York, NY, discuss several updates in the field of MPNs. Topics covered include novel agents being explored in PV, clinical guidance for the use of JAK inhibitors in MF, and the growing role of combination approaches.
The post MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches appeared first on VJHemOnc.
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, Marek Trněný, MD, PhD, Charles University, Prague, Czech Republic, John Kuruvilla, MD, Princess Margaret Cancer Centre, Toronto, Canada, and Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, share some insights into the evolving treatment landscape in mantle cell lymphoma (MCL), commenting on the changing role of transplantation and the impact of novel agents.
The post iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma appeared first on VJHemOnc.
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Francine Foss, MD, Yale School of Medicine, New Haven, CT, Laurence de Leval, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland, Francois Lemonnier, MD, PhD, Henri Mondor University Hospital, Créteil, France, and Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discuss recent updates in the biology and treatment of T-cell lymphoma.
The post iwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphoma appeared first on VJHemOnc.
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, and Nelli Bejanyan, MD, Moffitt Cancer Center, Tampa, FL, discuss the most recent updates in transplantation and immunotherapies in AML, and further comment on how to improve outcomes for patients.
The post iwAL 2023 Session IV: Transplantation and immunotherapies in AML: improving patient outcomes appeared first on VJHemOnc.
While the treatment landscape of both Hodgkin and non-Hodgkin lymphoma (HL; NHL) has improved in recent years, there are several challenges associated with treating elderly patients in these disease settings. The presence of comorbidities, as well as the risk of treatment-related toxicities, makes the treatment of elderly patients an important area of research.
In this podcast, Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, and Jonathan Friedberg, MD, MMSc, University of Rochester, Rochester, NY, discuss challenges with classifying frailty in elderly patients with diffuse large B-cell lymphoma (DLBCL) and HL, as well as treatment options available to these patients.
The post Classifying frailty and approaching elderly patients with lymphoma appeared first on VJHemOnc.
The treatment and management of lower-risk myelodysplastic syndromes (LR-MDS) has remained a challenge in the field, and several studies are being conducted with the goal of improving the understanding of this disease. Furthermore, there have been recent updates to classification systems for MDS, including the Molecular International Prognostic Scoring System (IPSS-M).
In this podcast, you will hear from Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Rami Komrokji, MD, Moffitt Cancer Center, Tampa, FL, who discuss recent updates in the diagnosis, risk stratification and treatment of LR-MDS. This discussion was filmed at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
The post Updates on the diagnosis, risk stratification and treatment of lower-risk MDS appeared first on VJHemOnc.
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Andrew Wei, MBBS, PhD, Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, Australia, and Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discuss the relevance of TP53 mutation in AML, highlighting prognostic approaches and therapeutic strategies for this patient population.
The post iwAL 2023 Session III: The relevance of TP53 mutation in AML appeared first on VJHemOnc.
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, Harry Erba, MD, PhD, Duke University, Durham, NC, and Jessica Altman, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, discuss new treatments in AML, drawing focus on FLT3 inhibitors, novel combinations, and treating patients with relapsed disease.
The post iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more appeared first on VJHemOnc.
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Ravi Majeti, MD, PhD, Stanford University, Stanford, CA, Courtney DiNardo, MD, MSCE, The University of Texas MD Anderson Cancer Center, Houston, TX, Uma Borate, MBBS, The Ohio State University Comprehensive Cancer Center, Columbus, OH, and Koichi Takahashi, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discuss clonal hematopoiesis (CH) in AML, early detection and intervention, and potential therapeutic strategies.
The post iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics appeared first on VJHemOnc.
Measurable residual disease (MRD) has become a key biomarker in the field of multiple myeloma (MM), and the sensitivity of...
The post Applications of MRD in multiple myeloma: using MRD to guide treatment decisions appeared first on VJHemOnc.
The treatment and management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains a major unmet need, and in recent...
The post Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL appeared first on VJHemOnc.
Myelodysplastic syndromes (MDS) represent a heterogeneic group of disorders which remain a challenge to diagnose and treat. In recent years,...
The post Pre-MDS states: improving prognosis, novel therapeutic approaches, and challenges with distinguishing these conditions appeared first on VJHemOnc.
Patients with BCR-ABL negative myeloproliferative neoplasms (MPNs) are at risk of progressing to accelerated-phase or blast-phase disease (MPN-AP/BP). Several mutations, including...
The post Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored appeared first on VJHemOnc.
Bispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope for patients with relapsed/refractory...
The post Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma appeared first on VJHemOnc.
CAR-T therapy has become a promising novel option for patients with relapsed/refractory (R/R) hematological malignancies, providing hope to several individuals...
The post Overcoming barriers to CAR-T therapy: improving access and cost appeared first on VJHemOnc.
Myeloproliferative neoplasms (MPNs) represent a challenging group of diseases to treat, and patients with MPNs suffer from several symptoms which...
The post The importance of addressing quality of life and improving symptom management in MPNs appeared first on VJHemOnc.
Amyloidosis is a rare disease in which insoluble amyloid proteins are deposited in tissues or organs, resulting in organ damage....
The post Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team appeared first on VJHemOnc.
Over the years, the hemophilia treatment landscape has transformed, with novel agents aiming to improve patient care and quality of...
The post Hemophilia: the current standard of care and the value of novel gene therapies appeared first on VJHemOnc.
Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL), with both covalent and non-covalent...
The post CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors appeared first on VJHemOnc.
In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients...
The post Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice appeared first on VJHemOnc.
The treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies including bispecific antibodies and...
The post Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management appeared first on VJHemOnc.
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought...
The post iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials appeared first on VJHemOnc.
Therapeutic agents for patients with myelodysplastic syndromes (MDS) are currently under active investigation in clinical trials. The management of cytopenias, including anemia, is an important component in the treatment of lower-risk MDS (LR-MDS), and many agents are being evaluated to better manage these. In the context of higher-risk MDS (HR-MDS), many patients may fail to respond to novel agents and the reasons for these failures are a key topic of discussion in the field.
In this podcast, you will hear from Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, and Valeria Santini, MD, University of Florence, Florence, Italy, as they discuss the management of anemia in LR-MDS and strategies to overcome treatment failure in HR-MDS. This discussion was filmed at the 17thInternational Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
The post MDS 2023 highlights: managing anemia in lower-risk MDS & overcoming treatment failure in higher-risk disease appeared first on VJHemOnc.
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in chronic lymphocytic leukemia (CLL), lymphoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and more.
In this podcast, you will hear from David Sallman, MD, Moffitt Cancer Center, Tampa, FL, Marion Subklewe, MD, Ludwig-Maximilians University, Munich, Germany, and Roman Shapiro, MD, Dana-Farber Cancer Institute, Boston, MA, who discuss major challenges with CAR-T therapy in AML, strategies to improve outcomes for patients, and more.
The post iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes appeared first on VJHemOnc.
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in chronic lymphocytic leukemia (CLL), lymphoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and more.
In this podcast, you will hear from leading experts Bijal Shah, MD, Moffitt Cancer Center, Tampa, FL, Rebecca Gardner, MD, Seattle Children’s Hospital, Seattle, WA, Claire Roddie, MD, PhD, University College London Hospitals NHS Foundation Trust, London, UK, and Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, who discuss the latest updates with CAR-T therapy in ALL. The experts share some insights into challenges with implementing CAR-T therapy in this disease, and further explain strategies to improve the efficacy of these agents.
The post iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks appeared first on VJHemOnc.
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in chronic lymphocytic leukemia (CLL), lymphoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and more.
In this podcast, you will hear from Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Tycel Phillips, MD, City of Hope, Duarte, CA, and Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, who share some updates on CAR-T therapy in lymphoma, and further discuss where bispecific antibodies may fit in the treatment landscape.
The post iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies appeared first on VJHemOnc.
The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and researchers who discussed several topics. In this podcast series, you will hear the latest updates in the treatment of multiple myeloma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York City, NY, Pieter Sonneveld, MD, PhD, Erasmus University, Rotterdam, The Netherlands, and Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discuss the possibility of reaching a cure in multiple myeloma, and further highlight concepts that need to be addressed to deliver this to patients.
The post iwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressed appeared first on VJHemOnc.
Myeloproliferative neoplasms (MPNs) represent a heterogeneous group of diseases which remain a challenge to treat. While there have been several advances in the MPN treatment landscape, allogeneic stem cell transplantation (alloSCT) remains the only curative option for patients. There are several important factors to consider when selecting patients for transplant, and the introduction of novel targeted therapies may further impact the role of alloSCT in MPNs.
In this podcast, you will hear from Ruben Mesa, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, Jeanne Palmer, MD, Mayo Clinic, Phoenix, AZ, Claire Harrison, MD, FRCP, FRCPath, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, and Haris Ali, MD, City of Hope, Duarte, CA, who discuss the current role of alloSCT in MPNs and how this may change with novel agents.
The post The current role of stem cell transplantation in MPNs & how this may change with novel agents appeared first on VJHemOnc.
The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and researchers who discussed several topics. In this podcast series, you will hear the latest updates in the treatment of multiple myeloma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, Lawrence Boise, PhD, Winship Cancer Institute of Emory University, Atlanta, GA, and Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, discuss the tumor microenvironment, the immune microenvironment, and mechanisms of resistance to agents including IMiDs, bispecifics and CAR-T cells.
The post iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies appeared first on VJHemOnc.
The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and researchers who discussed several topics. In this podcast series, you will hear the latest updates in the treatment of multiple myeloma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Leif Bergsagel, MD, Mayo Clinic, Phoenix, AZ, Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, and Niels Weinhold, PhD, University Hospital Heidelberg, Heidelberg, Germany, discuss the genomics of high-risk multiple myeloma and smoldering myeloma. Topics covered include the importance of next-generation sequencing (NGS), the role of del(17p) and TP53 mutations, and more.
The post iwMyeloma Session I: genomics of high-risk and smoldering multiple myeloma appeared first on VJHemOnc.
Allogeneic stem cell transplantation (alloSCT) remains a valuable treatment option for fit patients with acute myeloid leukemia (AML), and the importance of measurable residual disease (MRD) monitoring in this malignancy is well established. Several clinicians and researchers are conducting trials to further evaluate how to improve outcomes for patients undergoing alloSCT.
In this podcast, you will hear from Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, and Christopher Hourigan, MD, DPhil, National Institutes of Health, Bethesda, MD, who discuss the important role of transplantation in AML, the value of pre-transplant MRD, and more. This discussion was filmed at the 18th International Symposium on Acute Leukemias (ISALXVIII), held in Munich, Germany.
The post The important role of transplantation in AML: improving outcomes for patients & the value of pre-transplant MRD appeared first on VJHemOnc.
Although several novel agents have been implemented in the treatment of Hodgkin and non-Hodgkin lymphoma (HL; NHL), chemotherapy remains the backbone of treatment, both in the frontline and relapsed settings.
In this podcast, you will hear from Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, who shares some insights into the current role of chemotherapy in HL and various subtypes of NHL, and further explains how novel therapies, including CAR-T cells and antibodies, are changing the treatment landscape of these diseases.
The post Insights into the changing role of chemotherapy in lymphoma appeared first on VJHemOnc.
Recently, the International Consensus Classification (ICC) and World Health Organization (WHO) classification systems for myelodysplastic syndromes (MDS) were updated and published. Although these two systems are similar, there are key differences which must be taken into consideration by clinicians when diagnosing patients.
In this podcast, experts Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Rami Komrokji, MD, and Somedeb Ball, MD, Moffitt Cancer Center, Tampa, FL, discuss the latest updates in the classification of MDS and share some insights into how these may impact clinical practice.
The post Comparing the ICC and WHO classifications for MDS and their impact on clinical practice appeared first on VJHemOnc.
CAR-T cell therapy represents a major breakthrough in the treatment of hematological malignancies, including multiple myeloma, non-Hodgkin lymphoma (NHL), and acute lymphoblastic leukemia (ALL). However, there are several toxicities associated with these agents, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections.
In this podcast, you will hear from experts Eleni Gavriilaki, MD, PhD, G. Papanikolaou Hospital, Thessaloniki, Greece, Kevin McNerney, MD, MSc, Johns Hopkins All Children’s Hospital, St. Petersburg, FL, and Andriyana Bankova, MD, University Hospital Zurich, Zurich, Switzerland, who share some insights into the treatment and management of these common toxicities.
The post Managing and treating toxicities associated with CAR-T therapy: CRS, ICANS & infections appeared first on VJHemOnc.
Over the years, the treatment landscape of B-cell acute lymphoblastic leukemia (B-ALL) has transformed with the implementation of novel immunotherapies, including CAR-T cells, antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs). Furthermore, chemotherapy-free regimens are being increasingly explored, with several ongoing trials evaluating these.
In this podcast, experts Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Ryan Cassaday, MD, University of Washington, Seattle, WA, share some insights into the growing role of immunotherapy in ALL. Topics covered include the value of novel agents, targeting CD7 in T-ALL, and the possibility of moving away from stem cell transplantation (SCT).
The post The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation appeared first on VJHemOnc.
In recent years, novel immunotherapies, including CAR-T cell therapy, have greatly improved treatment options for patients with hematological malignancies. Although CAR-T cells have demonstrated remarkable success in several diseases, including multiple myeloma, acute lymphoblastic leukemia (ALL), and non-Hodgkin lymphoma (NHL), there has been less success with these agents in patients with chronic lymphocytic leukemia (CLL).
In this podcast, you will hear from John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, and Adam Kittai, MD, Ohio State University, Columbus, OH, who share some insights into the current status of CAR-T therapy in CLL. The experts discuss challenges with developing efficacious CAR-T products for CLL, the possibility of combining CAR-T cells with ibrutinib, and further comment on the latest advances in CAR-T therapy for Richter’s transformation.
The post The current status of CAR-T therapy in CLL and challenges in this space appeared first on VJHemOnc.
Graft-versus-host disease (GvHD) is a common complication associated with allogeneic stem cell transplantation (alloSCT), and can occur in acute and chronic forms. Novel approaches are being explored to minimize the risk of GvHD and improve the overall success of alloSCT.
In this podcast, you will hear from experts Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, Shernan Holtan, MD, University of Minnesota, Minneapolis, MN, Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, and Christopher Kanakry, MD, National Cancer Institute, Bethesda, MD, who discuss the importance of addressing post-transplant complications, and further highlight current approaches to GvHD prophylaxis and treatment.
The post Managing and treating GvHD and other post-transplant complications appeared first on VJHemOnc.
Over the last two decades, treatment approaches for multiple myeloma have significantly changed, and measurable residual disease (MRD) assessment is being increasingly recognized as a valuable tool to monitor patient response to therapy. Although there are several clinical trials incorporating MRD status as a clinical endpoint, its use in the real-world setting remains unclear.
In this podcast, you will hear from experts Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Mattia D’Agostino, MD, University of Turin, Turin, Italy, and Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, who discuss the prognostic role of MRD in multiple myeloma, the value of MRD-guided treatment, and clinical trials in this space.
The post The role of MRD in multiple myeloma appeared first on VJHemOnc.
Myelodysplastic syndromes (MDS) represent a group of heterogeneous diseases which remain a challenge to treat, and several novel therapies are being explored for the treatment of patients, especially those with relapsed/refractory (R/R) or high-risk disease. Immune therapies including CAR-T therapy and monoclonal antibodies are a promising option for patients, and are being evaluated in MDS following their success in other hematological malignancies. However, several challenges need to be addressed before these can be applied in clinical practice.
In this podcast, you will hear from experts David Sallman, MD, Moffit Cancer Center, Tampa, FL, Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, and Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, who discuss novel immune therapies being explored in MDS, emphasizing the challenges and opportunities for CAR-T therapy in this space.
The post Novel immune therapies in MDS and challenges in this space appeared first on VJHemOnc.
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.
In this podcast, you will hear from experts Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, and Tycel Phillips, MD, City of Hope, Duarte, CA, who share their highlights in non-Hodgkin lymphoma (NHL). Topics covered include updates from the TRIANGLE trial (NCT02858258), the changing role of transplantation, and novel immunotherapies in the field.
The post NHL highlights at ASH 2022: Updates in MCL, the role of transplantation, and novel bispecific antibodies appeared first on VJHemOnc.
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.
In this podcast, you will hear from experts Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, and Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, who discuss key updates in myeloproliferative neoplasms (MPNs) presented at this year’s meeting. Topics covered include updates from the MOMENTUM trial (NCT04173494), the importance of combination approaches, and novel agents being explored, including calreticulin (CALR)-targeting antibodies.
The post MPN highlights at ASH 2022: Novel agents, combinations & the role of immunotherapy appeared first on VJHemOnc.
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.
In this podcast, you will hear from experts Kate Cwynarski, FRCP, FRCPath, PhD, University College Hospitals London NHS Foundation Trust, London, UK, and Swaminathan Iyer, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, who discuss key updates in T-cell lymphoma. Topics covered include the importance of real-world data (RWD) in this space, addressing CNS relapse, and novel treatment approaches being explored.
The post T-cell lymphoma highlights at ASH 2022: Unmet needs, clinical trial updates & future outlooks appeared first on VJHemOnc.
CD47 is a cell surface protein which is overexpressed in several cancer cells and appears to play an important role in a variety of hematological malignancies, including acute myeloid leukemia (AML), lymphoma, and myelodysplastic syndromes (MDS). Currently, several anti-CD47 agents are under investigation for MDS, with promising results being demonstrated in clinical trials.
In this exclusive podcast, you will hear from Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, and David Sallman, MD, Moffit Cancer Center, Tampa, FL, who discuss the important role of CD47 in MDS, agents under investigation, and other targets of interest in this space.
The post The importance of CD47 in MDS and other targets of interest appeared first on VJHemOnc.
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.
In this podcast, you will hear from Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, and Lindsey Roeker, MD, Memorial Sloan Kettering Cancer Center, New York, NY, who discuss recent updates in chronic lymphocytic leukemia (CLL). The experts comment on the role of doublet and triplet therapies in CLL, clinical trial updates, and further highlight the impact of novel Bruton’s tyrosine kinase (BTK) inhibitors in this space.
The post CLL highlights at ASH 2022: Clinical trial updates, novel BTK inhibitors & combination therapy appeared first on VJHemOnc.
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.
In this podcast, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, and Krina Patel, MD, Msc, The University of Texas MD Anderson Cancer Center, Houston, TX, share key updates in multiple myeloma presented at this year’s meeting. The experts comment on real-world experiences with access to CAR-T therapy, the importance of optimizing the sequencing of therapies, ongoing clinical trials in high-risk disease, and more.
The post Myeloma highlights at ASH 2022: Improving access to CAR-T therapy & future outlooks appeared first on VJHemOnc.
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.
In this podcast, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, and Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, discuss key updates in myelodysplastic syndromes (MDS) presented at this year’s meeting. Topics covered include the treatment of lower-risk and higher-risk disease, novel classification systems, clinical trial updates, and treatment options after failure to hypomethylating agents (HMAs).
The post Highlights in MDS at ASH 2022: Treating lower-risk & higher-risk disease, trial updates, & more appeared first on VJHemOnc.
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Laurie Sehn, MD, BC Cancer Agency, Vancouver, Canada, Carmelo Carlo Stella, MD, PhD, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan Italy, and David Straus, MD, Memorial Sloan Kettering Cancer Center, New York, NY, share some insights into novel therapies in non-Hodgkin lymphoma (NHL), drawing focus on the role of antibody-drug conjugates (ADCs). The experts discuss updates on the use of several ADCs, including brentuximab vedotin, loncastuximab tesirine, polatuzumab vedotin, and camidanlumab tesirine, and where these agents fit in the treatment landscape.
The post iwNHL Session V: Novel therapies in NHL – the role of ADCs appeared first on VJHemOnc.
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, and Carsten Müller-Tidow, MD, University Hospital Heidelberg, Heidelberg, Germany, discuss mechanisms of resistance to targeted therapies in AML, and the role of epigenetics.
The post iwAL 2022 Session V: Mechanisms of resistance to targeted therapies in AML appeared first on VJHemOnc.
Chronic lymphocytic leukemia (CLL) remains a challenging hematological malignancy to treat, and genomic testing has become increasingly important in this disease. Several genomic tests are commonly carried out prior to initiating treatment, including testing for TP53 aberrations, IgHV mutational status, and more.
In this podcast, you will hear from Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, Florence Cymbalista, MD, Hôpital Avicenne, Bobigny, France, and Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, who discuss the importance of genomic testing in CLL and how this impacts treatment decisions.
The post The importance of genomic testing in CLL and its role in clinical decision-making appeared first on VJHemOnc.
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children’s National Health System, Washington, DC, Jeremy Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA, Barbara Savoldo, MD, PhD, UNC School of Medicine, Chapel Hill, NC, and Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, discuss the latest updates in T-cell therapies for the treatment of NHL, commenting on real-world data on CD19-directed CAR-Ts, and exploring the potential of other T-cell therapies including CD30, CD20, and CD5-directed CAR-Ts in T-cell lymphomas.
The post iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells appeared first on VJHemOnc.
The treatment landscape of chronic lymphocytic leukemia (CLL) has transformed over the years with the increased use of Bruton’s tyrosine...
The post Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more appeared first on VJHemOnc.
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the...
The post iwAL 2022 Session IV: The evolving treatment landscape in ALL and the growing role of immunotherapies appeared first on VJHemOnc.
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in...
The post iwNHL Session III: Exploring the optimal management of R/R follicular lymphoma in an expanding treatment landscape appeared first on VJHemOnc.
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the...
The post iwAL 2022 Session III: Novel targets, combinations and treatment strategies in AML appeared first on VJHemOnc.
The 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) was held in Houston, TX, from September 28-October 1,...
The post Recent updates in CML: treatment strategies, clinical trials, and novel agents appeared first on VJHemOnc.
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in...
The post iwNHL Session II: Understanding and harnessing the immune microenvironment against lymphoma appeared first on VJHemOnc.
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the...
The post iwAL 2022 Session II: Novel treatment strategies in ALL appeared first on VJHemOnc.
Myelodysplastic syndromes (MDS) represent a heterogeneous group of diseases which remain a challenge to treat, and immune dysregulation has been...
The post The role of the innate immune system in MDS appeared first on VJHemOnc.
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in...
The post iwAL 2022 Session I: The standard of care in AML in 2022 appeared first on VJHemOnc.
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in...
The post iwNHL 2022 Session I: Advances in the treatment of T-cell lymphoma appeared first on VJHemOnc.
The 18th Meeting of the International Society of Amyloidosis (ISA) was held in Heidelberg, Germany, on 4-8 September, 2022. This...
The post ISA 2022: meeting highlights and recent updates in amyloidosis appeared first on VJHemOnc.
The 19th International Myeloma Society (IMS) Annual Meeting was held in Los Angeles, CA, and brought together experts in the field,...
The post Highlights from IMS 2022: managing high-risk & frail patients with myeloma and the prognostic value of MRD appeared first on VJHemOnc.
The 2022 Texas MPN Workshop was held in San Antonio, TX, and covered several fascinating topics in the field of...
The post Highlights from the 2022 Texas MPN Workshop: early intervention, disease progression & future targets appeared first on VJHemOnc.
The 1st International Workshop on Myelodysplastic Syndromes (iwMDS) 2022 was held in Miami, FL, and brought together leading experts in...
The post iwMDS 2022: Key highlights appeared first on VJHemOnc.
Multiple myeloma is a heterogeneous disease, and despite recent advances in therapeutic agents, several patients still relapse after therapy and...
The post Identifying high-risk myeloma and improving treatment strategies in these patients appeared first on VJHemOnc.
In recent years, the treatment and management of myelodysplastic syndromes (MDS) has improved, and several clinical trials are investigating novel...
The post Improving the efficiency of drug approvals in MDS appeared first on VJHemOnc.
Myeloproliferative neoplasms (MPNs) represent a group of rare and heterogeneous diseases which remain a challenge to treat. Several advances have...
The post Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment appeared first on VJHemOnc.
The treatment and management of myelodysplastic syndromes (MDS) remains a challenge due to the heterogeneity of the disease, and early...
The post The need for more effective first-line therapies in MDS appeared first on VJHemOnc.
There were several fascinating sessions and discussions at the Myeloma 2022 meeting that took place in Scottsdale, AZ. Topics that...
The post Myeloma 2022: day two highlights appeared first on VJHemOnc.
The treatment landscape of chronic lymphocytic leukemia (CLL) has greatly transformed over the years with the introduction of several agents,...
The post The promise of CAR-T therapy in CLL and challenges in the field appeared first on VJHemOnc.
The relationship between mutations and precursor states in myelodysplastic syndromes (MDS) is a growing area of research, and advances in...
The post Clonal hematopoiesis and pre-MDS states appeared first on VJHemOnc.
Several novel agents have been approved in the field of multiple myeloma and have greatly transformed the treatment landscape of...
The post T-cell engagers in multiple myeloma: current challenges and future outlooks appeared first on VJHemOnc.
Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms, and the treatment and management of high-risk MDS remains a...
The post High-risk MDS: unmet needs and future treatment approaches appeared first on VJHemOnc.
CAR-T therapies have been approved for use in several hematological malignancies, and have greatly improved treatment options for patients, especially...
The post The importance of patient-reported outcomes in CAR-T recipients appeared first on VJHemOnc.
CAR-T therapy has revolutionized the treatment landscape of several hematological malignancies, and ongoing clinical trials continue to provide valuable data...
The post CAR-T therapy in myeloma and lymphoma appeared first on VJHemOnc.
Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy that poses many challenges for diagnosis and treatment. While...
The post CAR-T therapy in AML: challenges and future outlooks appeared first on VJHemOnc.
Classification and risk stratification are crucial for the management and treatment of patients with myelodysplastic syndromes (MDS). For many years,...
The post Updates in classification and risk stratification in MDS appeared first on VJHemOnc.
Over the last few decades, advances in immunotherapies including CAR-T therapy have revolutionized the treatment of patients with relapsed/refractory (R/R)...
The post The current state of CAR-T therapy in lymphoma appeared first on VJHemOnc.
While multiple myeloma remains a challenging disease to treat, there have been several advances in the field over the years....
The post Myeloma treatment updates from EHA 2022 appeared first on VJHemOnc.
Classification and risk stratification are crucial for the management and treatment of patients with myelodysplastic syndromes (MDS). For many years,...
The post Updates in classification and risk stratification in MDS appeared first on VJHemOnc.
At the Myeloma 2022 meeting held in Scottsdale, AZ, there were several fascinating sessions that took place covering a variety...
The post Myeloma 2022: day one highlights appeared first on VJHemOnc.
Myelodysplastic syndromes (MDS) are a type of rare and heterogeneous hematological malignancy, and immune dysregulation plays a major role in...
The post Immune dysregulation and targeting in MDS appeared first on VJHemOnc.
Acute lymphoblastic leukemia (ALL) is an aggressive and heterogeneous disease with a high mortality rate. However, several advances have been...
The post The future of CAR-T therapy in ALL appeared first on VJHemOnc.
Multiple myeloma has seen many advances in recent years, and novel targeted agents are transforming the field. Several immunotherapies, including...
The post An insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDs appeared first on VJHemOnc.
Myeloproliferative neoplasms (MPNs) are a class of hematological cancers characterized by the excessive production of a particular blood cell. MPNs...
The post Key updates in the treatment and management of MPNs appeared first on VJHemOnc.
Amyloidosis is a heterogeneous disease that results from the deposition of abnormal protein aggregates in various tissues and organs. The...
The post Addressing unmet needs and future treatment approaches in AL amyloidosis appeared first on VJHemOnc.
While the treatment of multiple myeloma has seen several recent advances, challenges still remain when approaching patients with high-risk disease,...
The post Myeloma treatment in the UK: updates from Muk Nine b: OPTIMUM & the importance of genomics appeared first on VJHemOnc.
In recent years, there have been many advances in the treatment of lymphoma and chronic lymphocytic leukemia (CLL) in the...
The post Updates in lymphoma and CLL treatment in the UK appeared first on VJHemOnc.
Multiple myeloma is a heterogenous and complex disease, with many experts agreeing that screening for precursor conditions can improve patient...
The post The importance of early interception and intervention in myeloma appeared first on VJHemOnc.
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), which took place on 19-23 March...
The post Impact of the COVID-19 pandemic on the EBMT & projects in the pipeline appeared first on VJHemOnc.
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), which took place on 19-23 March 2022, was held virtually for the third time in a row due to the unprecedented humanitarian crisis in Ukraine. Despite the great success of this year’s Annual Meeting, the EBMT had to face significant challenges during these past two years of COVID-19 pandemic.
Join us for this insightful discussion where leading experts Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, and President of the EBMT Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, review the efforts of the EBMT during the COVID-19 pandemic, and comment on the impact of the pandemic on transplantation practices. Prof. Chabannon and Dr Sureda also discuss the relevance of stem cell transplantation within the context of CAR-T therapy and outline the EBMT’s future projects.
Lymphoma treatment has seen many recent advances, with CAR-T therapy being a game changer for patients. Several clinical trials investigating...
The post CAR-T and lymphoma treatment in the UK appeared first on VJHemOnc.
The myeloma treatment landscape has seen a lot of progress in the last few years, with several novel therapies emerging,...
The post Harnessing the power of immunotherapy in myeloma and amyloidosis appeared first on VJHemOnc.
Artificial intelligence (AI) and machine learning algorithms are transforming treatment and prognosis in hematological malignancies, as well as other areas...
The post The impact of AI and machine learning algorithms in MDS appeared first on VJHemOnc.
Despite significant advances in molecular profiling and treatments for multiple myeloma, patients with high-risk and ultra high-risk disease still have...
The post MMRF-CoMMpass: the genomic basis of myeloma subtypes appeared first on VJHemOnc.
Immunotherapies are at the forefront of myeloma treatment and there are many questions remaining. Defining high-risk is important when making...
The post Genomics in the age of immuno-oncology appeared first on VJHemOnc.
Relapsed/refractory (R/R) multiple myeloma remains an incurable hematological malignancy with an unmet clinical need. It is necessary to gain a...
The post Understanding multiple myeloma at the single-cell level appeared first on VJHemOnc.
Amyloidosis is a disease that results from the accumulation of a toxic, insoluble protein called amyloid in various tissues and...
The post Recent advances in amyloidosis treatment appeared first on VJHemOnc.
Various forms of immunotherapy represent a novel treatment option, especially for patients who progress from conventional chemotherapy hematopoietic stem-cell transplantation...
The post ASH 2021: a deep dive into ALL immunotherapy appeared first on VJHemOnc.
With high rates of relapse in patients with myelodysplastic syndromes (MDS), there is a great unmet need for novel treatments...
The post ASH 2021: what did ASH 2021 mean for MDS? appeared first on VJHemOnc.
The JAK-STAT pathway plays a pivotal role in the pathogenesis of myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and...
The post ASH 2021: novel developments in MPNs appeared first on VJHemOnc.
Multiple myeloma is always preceded by two precursor conditions known as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple...
The post ASH 2021: evaluating the impact of screening for MGUS and SMM appeared first on VJHemOnc.
Cell therapies including chimeric antigen receptor (CAR) T-cell therapy represent novel treatments for patients with lymphoma, especially for those who...
The post ASH 2021: the future of cell therapies in lymphoma appeared first on VJHemOnc.
Treatments such as ibrutinib and venetoclax, which target the Bruton tyrosine kinase (BTK) pathway and the B-cell lymphoma 2 (BCL-2) protein respectively, have proven to be efficacious as targeted therapies for previously untreated patients with chronic lymphocytic leukemia (CLL). For patients who have progressed on existing therapies, novel BTK inhibitors such as pirtobrutinib and MK1026 represent promising alternative treatment options.
In today’s podcast, Jennifer Woyach, MD and Adam Kittai, MD, Ohio State University College of Medicine in Columbus, OH, provide their perspectives on key themes and topics in the treatment and management of CLL. They evaluate findings from the CAPTIVATE, GLOW and CLL13 clinical trials, long-term follow up data of the ALLIANCE A041202 and SEQUOIA trials, novel agents and the role of MRD in CLL.
This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
The post ASH 2021: highlights in CLL clinical trials appeared first on VJHemOnc.
FMS-like tyrosine kinase 3 (FLT3) mutations are common in patients with acute myeloid leukemia (AML), and is often associated with a poor prognosis. Despite the development of FLT3 inhibitors such as midostaurin, sorafenib, and qauizartinib, patients often progress on these therapies due to secondary mutations. Various strategies to improve patient outcomes such novel combinations with other agents including hypomethylating agents or venetoclax are currently under investigation.
In this podcast, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, have an insightful discussion on FLT3-mutated acute myeloid leukemia (AML) updates presented at the ASH 2021 annual meeting. They give an overview of the use of FLT3 inhibitors in combination with other agents, as well as trial data from the LACEWING trial (NCT02752035) of gilteritinib in combination with azacitidine in the frontline setting. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
The post ASH 2021: updates in FLT3 mutated AML appeared first on VJHemOnc.
FMS-like tyrosine kinase 3 (FLT3) mutations are common in patients with acute myeloid leukemia (AML), and is often associated with a poor prognosis. Despite the development of FLT3 inhibitors such as midostaurin, sorafenib, and qauizartinib, patients often progress on these therapies due to secondary mutations. Various strategies to improve patient outcomes such novel combinations with other agents including hypomethylating agents or venetoclax are currently under investigation.
In this podcast, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, have an insightful discussion on FLT3-mutated acute myeloid leukemia (AML) updates presented at the ASH 2021 annual meeting. They give an overview of the use of FLT3 inhibitors in combination with other agents, as well as trial data from the LACEWING trial (NCT02752035) of gilteritinib in combination with azacitidine in the frontline setting.
This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
The 63rd American Society of Hematology (ASH) annual meeting saw a plethora of updates in lymphoma. While most of them generated a lot of fruitful conversations, some of the breakthroughs have the potential to change practice.
In this roundtable discussion, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, review the most exciting updates in lymphoma from the 2021 ASH annual meeting and reflect on how the data may impact clinical practice in the UK.
The post The Lymphoma Sessions: post-ASH 2021 appeared first on VJHemOnc.
The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately 30% of patients with acute myeloid leukemia (AML) and is indicative of a poor prognosis. Allogeneic hematopoietic stem cell transplantation (alloHSCT) is commonly recommended to this patient population as a consolidation therapy after first complete remission. Nevertheless, the rate of relapse post-alloHSCT remains high and effective post-transplant maintenance therapies represent an unmet clinical need. The FLT3 tyrosine kinase inhibitors (TKIs), including sorafenib, midostaurin and gilteritinib, have demonstrated improved outcomes for patients undergoing alloHSCT. Multiple ongoing trials are currently investigating these agents as maintenance therapies.
In this deep dive, Andreas Burchert, MD, University of Marburg, Marburg, Germany, discusses updates on post-transplant maintenance therapies for patients with FLT3+ AML, focusing on data from clinical trials evaluating four tyrosine kinase inhibitors: sorafenib, midostaurin, gilteritinib and quizartinib, as presented at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM).
The post COSTEM: maintenance therapies for FLT3+ AML appeared first on VJHemOnc.
Over the past few years, the therapeutic landscape for acute lymphoblastic leukemia (ALL) has dramatically evolved, with the development of highly effective tyrosine kinase inhibitors (TKIs) and bispecific antibodies. These therapies have considerably improved outcomes for patients and many achieve durable remissions, raising the debate of whether allogeneic hematopoietic stem cell transplantation (alloHSCT) should still be offered to all patients with ALL.
In this podcast featuring Mohamad Mohty, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, and Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discuss the relevance of alloHSCT in the current therapeutic landscape for ALL.
The post COSTEM: the role of alloHSCT in ALL appeared first on VJHemOnc.
Over the last two decades the outcomes of patients with amyloidosis have substantially improved with timely diagnosis, the use of chemotherapeutic agents, and improved patient selection for autologous stem cell transplantation (ASCT); however, for patients who are diagnosed at later stages or who are ineligible for ASCT the prognosis is poorer. Recently, the introduction of daratumumab has shown promising results for patients with both newly diagnosed and relapsed/refractory amyloidosis and there have been a number of Phase II/III trials aiming to help guide treatment decision-making and improve patient outcomes.
In today’s podcast, Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, gives an overview of key updates in the treatment landscape of amyloidosis, as presented at the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
The post SOHO 2021: amyloidosis treatment updates appeared first on VJHemOnc.
Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia, B-cell lymphoma, non-Hodgkin lymphoma and multiple myeloma. Despite reporting high response rates, the use of CAR-T therapy is associated with a number of challenges, including treatment-related adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), as well as high costs and manufacturing difficulties. It is thus crucial to reduce the incidence and optimize the management of toxicities through careful patient selection and monitoring. CAR-T therapy is also being explored as a treatment option for chronic lymphocytic leukemia (CLL), where attempts with CAR-T have been unsuccessful due to CLL-induced T-cell dysfunction, a process that is not well understood.
In this podcast, Arnon Nagler, MD, MSc, of the Chaim Sheba Medical Center, Tel-Hashomer, Israel, Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, Barcelona, Spain, Christian Chabannon, MD, PhD, of the Institut Paoli Calmettes, Marseille, France, and Arnon Kater, MD, PhD, of the University of Amsterdam, Amsterdam, Netherlands, discuss key considerations for the use of CAR-T therapy in clinical practice, as presented at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH) 2021.
The post IACH 2021: CAR-T in clinical practice appeared first on VJHemOnc.
The treatment of chronic myeloid leukemia (CML) has substantially evolved since the FDA approval of the tyrosine kinase inhibitor imatinib in 2001 – the first targeted therapy for CML. Since then, several second- and third- generation TKIs have emerged in the field, as well as other novel therapies. Despite this, around 20-30% of patients with CML will require changes of treatment due to resistance, intolerance or suboptimal responses and thus alternative treatment approaches are needed.
In this podcast, Joaquin Martinez-Lopez, MD, PhD, of the Universidad Complutense de Madrid, Madrid, Spain, gives a brief overview of unmet needs and novel therapeutic approaches for patients with CML, as discussed at the 18th International Myeloma Workshop (IMW 2021).
The post Unmet needs and recent updates in CML appeared first on VJHemOnc.
Continuous therapy has been a key aspect of the standard of care approaches for the treatment of multiple myeloma for many years, prolonging disease control and improving progression-free survival in comparison to fixed-duration approaches; however, it is now being discussed whether treatment-free interval strategies could be incorporated into the treatment paradigm. Evidence from the IFM/DFCI2009 (NCT01191060) study has suggested that patients with myeloma who achieve measurable residual disease (MRD) negativity have good outcomes without continuous treatment, and similar findings have been reported in part 2 of the Phase III Cassiopeia (NCT02541383) trial. Despite this, potential surrogate markers, such as MRD, still require validation in order to determine patient eligibility for management strategies involving treatment-free intervals in multiple myeloma.
In this podcast, Phil McCarthy, MD, of the Roswell Park Comprehensive Cancer Center, Buffalo, NY, and Luciano Costa, MD, PhD, of the UAB School of Medicine, Birmingham, AL, discuss the evidence for and against treatment-free intervals in the treatment of multiple myeloma, as debated at the 18th International Myeloma Workshop (IMW 2021).
The post IMW 2021: treatment-free intervals in multiple myeloma appeared first on VJHemOnc.
The management of chronic lymphocytic leukemia (CLL) has evolved drastically over the last few years, with the introduction of novel therapies and the identification of new genetic markers. The current most effective therapies for CLL include venetoclax, obinutuzumab and BTK inhibitors, whilst ongoing clinical trials are investigating the use of BTK inhibitors in combination with BCL-2 inhibitors. Furthermore, novel genomic markers are increasingly being used to guide treatment decisions, as well as for prediction and prognostication purposes, and research into the optimal sequencing of targeted therapies is also showing promise in improving outcomes for patients who develop resistance to BCL-2 and BTK inhibitors.
In this podcast, Paolo Ghia, MD, PhD, of Università Vita-Salute San Raffaele and the IRCCS Ospedale San Raffaele, Milan, Italy, Barbara Eichhorst, MD, of University Hospital Cologne, Cologne, Germany, Lydia Scarfò, MD, of Vita-Salute San Raffaele University & the IRCCS San Raffaele Scientific Institute, Milan, Italy, Adrian Wiestner, MD, PhD, of the National Institutes of Health, Bethesda, MD, and Richard Rosenquist, MD, of the Karolinska Institute, Stockholm, Sweden, share some of the latest updates in CLL treatment, as presented at the 19th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting in 2021.
The post Highlights from iwCLL 2021 appeared first on VJHemOnc.
Measurable residual disease (MRD) is emerging as an important prognostic marker in the management of multiple myeloma. Promising clinical evidence from trials, such as the MYELOMA XI trial, has linked MRD-negativity to improved outcomes in myeloma. Whilst research into MRD as a prognostic marker continues, MRD is further being explored as a tool to guide the adaptive treatment of patients with myeloma, such as by intensifying treatment for MRD-positive patients, or by de-escalating treatment for MRD-negative patients. Future trials investigating the relative safety and efficacy of MRD-guided adaptive treatment will help to determine the optimal role of MRD in multiple myeloma.
In this podcast, Natalie Callander, MD, of the University of Wisconsin School of Medicine and Public Health, Madison, WI, Luciano Costa, MD, PhD, of the UAB School of Medicine, Birmingham, AL, Fredrik Schjesvold, MD, PhD, of the Oslo Myeloma Center Oslo University, Oslo, Norway, Lanny Kirsch, MD, Senior Vice President in Translational Medicine at Adaptive Biotechnologies, Seattle, WA, and Philippe Moreau, MD, of the Nantes University Hospital, Nantes, France, discuss the latest data on the use of MRD in the management and treatment of multiple myeloma, as presented at the 18th International Myeloma Workshop (IMW 2021).
The post IMW 2021: MRD in myeloma appeared first on VJHemOnc.
Autologous stem cell transplantation (ASCT) has been the standard of care patients with multiple myeloma for the past three decades; however, high-risk patients still have poor outcomes. Many bispecific antibody therapies are currently under investigation for the treatment of myeloma, such as blinatumomab, teclistamab, talquetamab and cevostamab, and the chimeric antigen receptor (CAR) T-cell therapy, idecabtagene vicleucel, became the first CAR-T therapy to receive FDA approval for the treatment of multiple myeloma in March 2021. With CAR-T and bispecific antibodies demonstrating deep and sustained remissions, the role of ASCT in the future treatment of myeloma has become a subject of debate.
In this podcast, Hermann Einsele, MD, FRCP, of the University of Würzburg, Würzburg, Germany, and Parameswaran Hari, MD, MRCP, MS, of the Froedtert Hospital Cancer Center, Milwaukee, WI, discuss the benefits and drawbacks of CAR-T and bispecific antibodies as a replacement for ASCT in multiple myeloma.
The post CAR-T vs bispecifics: replacing ASCT in myeloma appeared first on VJHemOnc.
Antibody therapies are rapidly transforming the treatment landscape of non-Hodgkin lymphoma (NHL). Since the development of rituximab as an anti-CD20 antibody, there has been an intense research interest in antibody-based therapeutic approaches. The use of antibody-drug conjugates, monoclonal antibodies, and bispecific antibodies are increasingly being investigated in clinical trials for the treatment of NHL, particularly in diffuse large B-cell lymphoma (DLBCL) and in the relapsed/refractory setting, offering alternative strategies for disease management.
In this podcast, Gilles Salles, MD, PhD, of the Memorial Sloan Kettering, New York, NY, Martin Hutchings, MD, PhD, of the Copenhagen University Hospital, Copenhagen, Denmark, Moshe Yair Levy, MD, of the Baylor Charles A. Sammons Cancer Center, Dallas, TX, Paolo Caimi, MD, of the University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, and Nilanjan Ghosh MD, PhD, of the Levine Cancer Institute, Charlotte, NC, discuss the latest clinical updates on the use of antibody therapies for the treatment of NHL, as presented at the European Hematology Association (EHA) Congress 2021 and the International Conference on Malignant Lymphoma (ICML), 2021.
A significant number of patients with acute myeloid leukemia (AML) are unable to withstand intensive chemotherapy regimens due to older age and the presence of comorbidities, creating an unmet medical need. Recent advances in the understanding of the genomics underlying AML have led to the development of therapies targeting FLT3, IDH1/2 and BCL-2. Between 2017 and 2018 the US FDA approved a total of eight drugs for AML, including glasdegib, venetoclax, ivosidenib, midostaurin and gemtuzumab ozogamicin. Many trials are now reporting longer follow-up data on these drugs as well as on novel combinations and approaches.
In this podcast, Andrew Brunner, MD, of the Massachusetts General Hospital, Boston, MA, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Stéphane de Botton, MD, PhD, of the Gustave Roussy Institute, Paris, France, and Andrius Zucenka, MD, of the Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, share updates on novel therapies for the treatment of AML, as presented at the European Hematology Association (EHA) 2021 congress.
Janus kinase (JAK) inhibitors are becoming an increasingly prominent class of drug in the treatment of myeloproliferative neoplasms (MPNs), in particular for the management of myelofibrosis symptoms. With the FDA approval of ruxolitinib in 2011 followed by the approval of fedratinib in 2019, JAK inhibitors are already established in the myelofibrosis treatment landscape; however, studies investigating novel JAK inhibitors could potentially lead to further approvals. Both pacritinib and momelotinib have demonstrated promising results in the PERSIST-2 trial and the SIMPLIFY-1 and SIMPLIFY-2 trials and continue to be explored in the ongoing MOMENTUM and PACIFICA trials, respectively.
In this podcast, Ruben Mesa, MD, of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, Aaron Gerds, MD, of the Cleveland Clinic, Cleveland, OH, and Abdulraheem Yacoub, MD, MBBS, of The University of Kansas, Westwood, KS, discuss the latest updates on JAK inhibitors for the treatment of MPNs, as presented at the Texas MPN Workshop: Second Annual Meeting and Workshop 2021.
Great progress has been made in the treatment of acute lymphocytic leukemia (ALL), primarily owing to the development of targeted therapies such as monoclonal antibodies and tyrosine kinase inhibitors. The use of targeted therapies has significantly improved survival outcomes for patients with ALL and has become a mainstay of frontline treatment. Since the FDA approval of blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel, clinical trials have been increasingly investigating combination regimens with these targeted agents with the goal of optimizing their use and reducing the need for cytotoxic therapies.
In today’s podcast, Bijal Shah, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, Daniel W. Lee, MD, of the University of Virginia, Charlottesville, VA, Nicholas Short, MD, of the MD Anderson Cancer Center, Houston, TX, and Robin Foà, MD, of the Sapienza University of Rome, Rome, Italy, talk on the latest clinical updates on the use of targeted therapies for the treatment of ALL, as presented at the European Hematology Association (EHA) Congress 2021.
Many clinical trials are currently investigating the potential benefits of interferons in the treatment of myeloproliferative neoplasms (MPNs), in particular for polycythemia vera, essential thrombocythemia and myelofibrosis. Interferon-alfa was originally explored for MPN treatment many years ago, however it’s frequent dosing and toxicity profile present barriers to widespread use. More recently, ropeginterferon-alfa-2b-vjft reported promising results for patients with polycythemia vera in the PROUD and CONTINUATION-PV clinical trials (NCT01949805; NCT02218047) and is now being reviewed for approval by the FDA, and pegylated-interferon-alfa has also demonstrated efficacy.
In this podcast, we hear from Richard Silver, MD, and Nicole Kucine, MD, MS, both from the Weill Cornell Medical College, New York, NY, who share the latest clinical updates on the use of interferons for the treatment of polycythemia vera and essential thrombocythemia, as presented at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
Real-world data gained through scientific studies is essential in the advancement of treatments for all hematologic malignancies. Historically, pharmaceutical companies have been restricted to randomized clinical trials as their only form of testing a treatment. However, due to technological advancement, there are now ways in which data from real-world treatment settings can be collected by clinical researchers. Real-world data is used to support decision making regarding the usage, overall benefits, and risks associated with specific drugs and therapeutic combinations.
In this podcast, David Miklos, BSc, MD, PhD, of Stanford University, Stanford, CA, Elena Zamagni, MD, PhD, of the University of Bologna, Bologna, Italy, Heinz Ludwig, MD, of the Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, and Andrea Visentin, MD, PhD, of the University of Padua, Padova, Italy, discuss some of the latest real-world data to have been shared in the fields of lymphoma, myeloma and chronic lymphocytic leukemia (CLL), as presented at the European Hematology Association (EHA) Congress 2021.
Over the past two decades the treatment landscape for non-Hodgkin lymphoma (NHL) has rapidly evolved, with the development of Bruton’s tyrosine kinase (BTK) inhibitors making a particularly significant impact and opening the door to the possibility of chemotherapy-free regimens. In 2013, ibrutinib became the first BTK inhibitor to receive FDA approval for the treatment of follicular lymphoma, followed by approvals for Waldenström’s macroglobulinemia and marginal zone lymphoma in 2015 and 2017 respectively. Since then, the BTK inhibitors acalabrutinib and zanubrutinib have received FDA approval and many trials are exploring novel BTK inhibitors and combinations.
In today’s episode, Thomas Witzig, of the Mayo Clinic Rochester, Rochester, MN, Chan Yoon Cheah, of the Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, Gilles Salles of the Memorial Sloan Kettering Cancer Center, New York City, NY, and Paolo Ghia of Università Vita-Salute San Raffaele, Milan, Italy, talk on the latest data from key clinical trials of BTK inhibitors for the treatment of NHL.
Research into the treatment of non-Hodgkin lymphoma (NHL) has made great progress within the last decade, with clinical trials such as the TRANSCEND-OUTREACH-007 and ZUMA-12 studies successfully advancing into later phases. Although there are currently various approaches to NHL treatment, primarily employing chemotherapy, steroid medication and allogeneic stem cell transplantation, such approaches are not tolerated by all patients and may not achieve complete remissions, creating an opening for immunotherapies to address these challenges. Given the recent FDA approvals of chimeric antigen receptor T-cell (CAR-T) therapies such as idecabtagene vicleucel and lisocabtagene maraleucel, much attention has now turned to the potential of these novel cellular therapies for more effective treatment of NHL.
In this podcast, Jeremy Abramson of the Massachusetts General Hospital Cancer Center, Boston, MA, Sattva Neelapu of the University of Texas MD Anderson Cancer Center, Houston, TX, Stephen Schuster of the Perelman School of Medicine, Philadelphia, PA, Barbara Savoldo of the University of North Carolina at Chapel Hill, Chapel Hill, NC, Max Mamonkin of the Baylor College of Medicine, Houston, TX, and Susan Prockop of the Memorial Sloan Kettering Cancer Center, New York, NY, discuss the latest clinical updates on T-cell therapies for NHL, highlighting therapies such as lisocabtagene maraleucel and axicabtagene ciloleucel.
Immunotherapies are showing increasingly promising results for the treatment of patients with non-Hodgkin lymphoma (NHL) and, in particular, bispecific antibodies have demonstrated promising clinical results in heavily pre-treated patients. Several bispecific antibodies have entered the early stages of clinical trials since the approval of the CD19/CD30 bispecific antibody blinatumomab, and recently CD20/CD3 bispecific antibodies have demonstrated encouraging response rates in patients with both aggressive and indolent NHL.
In today’s podcast, Stephen Schuster from the Perelman School of Medicine, Philadelphia, PA, Franck Morschhauser from Lille University Hospital, Lille, France, and Rajat Bannerji from the Rutgers Cancer Institute of New Jersey, Newark, NJ, discuss the latest data on CD20/CD3 bispecific antibodies for the treatment of patients with NHL, in particular talking on mosunetuzumab, CD20-TCB and odronextamab, previously known as REGN1979.
At present, four types of chimeric antigen receptor T-cell (CAR-T) therapy are FDA approved for specific types of lymphoma: for relapsed or refractory (R/R) mantle cell lymphoma, brexucabtagene autoleucel, for R/R follicular lymphoma, axicabtagene ciloleucel, and for some aggressive forms of non-Hodgkin lymphoma, axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel. Despite these approvals, progression of disease and toxicity remain unresolved concerns associated with CAR-T therapy which are currently being investigated.
In this podcast, Caron Jacobson of the Dana-Farber Cancer Institute, Boston, MA, Stephen Schuster of the Perelman School of Medicine, Philadelphia, PA, Jeremy Abramson of the Massachusetts General Hospital Cancer Center, Boston, MA, Frederick Locke of the H. Lee Moffitt Cancer & Research Institute, Tampa, FL, David Miklos of Stanford University, Stanford, CA, Mazyar Shadman of the Fred Hutchinson Cancer Research Center, Seattle, WA, and Sonali Smith of the University of Chicago, Chicago, IL, discuss the latest updates on CAR-T therapy for the treatment of lymphoma.
Although classical Hodgkin lymphoma has a high cure and overall survival rate, the treatment of relapsed/refractory disease, treatment-related adverse events, quality of life and poor outcomes in older patients present ongoing unmet needs. Much research is currently focused on risk stratification, such as with positive emission tomography (PET) scans, to identify patients who are at low- or high-risk of recurrence and enable the use of risk-adapted approaches. Furthermore, longer-term follow-up data from trials of novel immunotherapy combinations in the frontline setting have recently been presented which demonstrate durable remissions and may reduce the risk of relapse for patients with classical Hodgkin lymphoma.
In this podcast, Julia Driessen, MBBS, University of Amsterdam, Amsterdam, The Netherlands; Ann LaCasce, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA; Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, and Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, share updates on the use of PET in the treatment and management of Hodgkin lymphoma, as well as five-year follow-up data from the ECHELON-1 and CheckMate 205 trials, as presented at the 2021 International Conference on Malignant Lymphoma (ICML) and this year’s European Hematology Association (EHA) Congress.
Hematopoietic stem cell transplantation (HSCT) is used as a treatment option for a wide variety of hematological disorders. Graft-versus-host disease (GvHD) is a systemic disorder that arises when the graft’s immune cells recognize the host as foreign and attack the recipient’s body cells. Its occurrence poses a major medical complication that limits the efficacy of HSCT and causes significant morbidity and mortality. New insights into the pathophysiology of GvHD have led to new developments in treatment strategies. Additionally, immediate survival is no longer the only concern after allogeneic HSCT (allo-HSCT). The burden of long-term morbidity borne by allo-HSCT survivors is substantial, and patients who received allo-HSCT have recently been identified as being at increased risk of cardiovascular events.
In this exclusive podcast, John Koreth, MBBS, PhD, of the Dana-Farber Cancer Institute, Boston, Massachusetts, Eduardo Rodríguez-Arbolí, MD, MPhil, Hospital Universitario Virgen del Rocío, Seville, Spain, and Eleni Gavriilaki, MD, PhD, of the National and Kapodistrian University of Athens, Greece, provide the latest transplant updates, as presented at this year’s Congress of the European Hematology Association (EHA 2021).
The treatment of multiple myeloma is a rapidly evolving field with advances in the understanding of myeloma disease biology contributing to the development of novel targeted therapies. Recently, there has been a rapid increase in the number of chimeric antigen receptor (CAR) T-cell therapies being trialed for patients with multiple myeloma, and in March 2021, idecabtagene vicleucel became the first CAR-T therapy to receive FDA approval for the treatment of myeloma.
In this podcast, Nina Shah of the University of California San Francisco, CA; Saad Usmani of the Levine Cancer Institute, NC; Sham Mailankody of the Memorial Sloan Kettering Cancer Centre, NY; Adam Cohen of the Abramson Cancer Centre, PA; and Maria-Victoria Mateos of the University Hospital of Salamanca, Spain, discuss the use of CAR-T therapy in patients with multiple myeloma.
In this roundtable discussion, chaired by Gilles Salles, MD, PhD, Memorial Sloan Kettering, New York, NY; Nirav N. Shah, MD, Medical College of Wisconsin, Brookfield, WI; Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria; Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, review the most exciting updates in lymphoma from the 2021 European Hematology Association (EHA) and International Conference on Malignant Lymphoma (ICML) meetings, highlighting the latest data on antibody, cellular and novel therapies.
In this roundtable discussion, chaired by Paolo Ghia, MD, PhD, Università Vita-Salute San Raffaele, Milan, Italy; Susan O’Brien, MD, University of California Irvine, Irvine, CA; Lydia Scarfò, MD, Università Vita-Salute San Raffaele, Milano, Italy and Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, review the most exciting updates in chronic lymphocytic leukemia (CLL) from the 2021 European Hematology Association (EHA) and International Conference on Malignant Lymphoma (ICML) meetings, including the latest data from the RESONATE-2, CLL14, MURANO and ELEVATE-RR trials, as well as talking on second-generation BTKs and fixed-duration therapy.
Myelodysplastic syndromes (MDS) are a group of myeloid clonal disorders caused by a defect in bone marrow, which hinders their ability to produce healthy and normal functioning red blood cells (RBCs). The heterogeneous nature of MDS means therapeutic approaches need to be specifically tailored to each subtype. Current treatment options for MDS include allogeneic hematopoietic stem cell transplantation, which is the only curative form of treatment and available to only a small population of patients, whilst for most patients, non-curative treatment such as iron chelation and growth factors, lenalidomide and hypomethylating agents are the only available options. Although progress has been made in understanding the mechanisms which underpin MDS, few novel treatments have been developed.
In this podcast, Valeria Santini, MD, University of Florence, Florence, Italy; Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia; and Sangmin Lee, MD, Weill Cornell Medicine, New York, NY, discuss the latest research on treatment for MDS, as presented at this year’s Congress of the European Hematology Association (EHA 2021).
Recent progress in the field of immunotherapy presents an exciting alternative to standard chemotherapy treatments for patients with non-Hodgkin lymphoma. However, at present, durable responses are only achieved in a minority of patients. Accumulating evidence suggests that the microenvironment plays a critical role in the regulation of immunotherapeutic agents. Furthering our understanding of this relationship may help to enhance the outcomes of current immunotherapy regimens and improve the development of novel immunotherapies.
In this podcast, Patricia Pérez Galán of the IDIBAPS University Hospital Clinic, Barcelona, Spain, Stephen Ansell of the Mayo Clinic, Rochester, MN, Frederick Locke of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, and Francisco Hernandez-Ilizaliturri of the Roswell Park Cancer Institute, Buffalo, NY, talk on the impact and role of the tumor microenvironment on outcomes with immunotherapy in patients with non-Hodgkin lymphoma.
The introduction of many novel drug classes and therapies has resulted in significant improvements in overall survival outcomes for patients with multiple myeloma over the past decade. Despite this, many patients become relapsed or refractory to currently available therapies and as such, novel agents and combination regimens remain key to improving the outcomes of patients in high-risk subgroups. Immunotherapies, such as monoclonal antibodies, and chimeric antigen receptor T-cell (CAR-T) therapies have become increasingly prominent in the multiple myeloma space, with the first CAR-T therapy for myeloma receiving FDA approval in March 2021. However, with such a broad range of treatments now available, there is debate on the optimal sequencing of therapies.
In this roundtable discussion, chaired by Noopur Raje, MD, from the Massachusetts General Hospital, Boston, MA, Nina Shah, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, Yi Lin, MD, PhD, from the Mayo Clinic, Rochester, MN, and Katja Weisel, MD, from the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, review the most exciting updates from the 2021 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) meetings, including the latest data from the MAIA, FORTE and Cassiopeia trials, as well as talking on novel agents and CAR-T therapies.
The breakthrough discovery of upregulation of the JAK-STAT signaling pathway as the driving force behind myeloproliferative neoplasms (MPNs) has led to a broadened range of treatment options across the spectrum of MPNs. Myelofibrosis is one of the most common types of MPN and many clinical trials are exploring novel drugs and combinations for its treatment. The JAK inhibitor ruxolitinib became the first JAK inhibitor to receive FDA approval for the treatment of myelofibrosis in 2011, and more recently the FDA granted approval to fedratinib for patients with intermediate-2 or high-risk myelofibrosis.
In this podcast, Srdan Verstovsek, MD, from the MD Anderson Cancer Center, Houston, TX, Ruben Mesa, MD, from the UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, and Naveen Pemmaraju, MD, of the MD Anderson Cancer Center, discuss the key updates from clinical trials investigating novel therapies and treatment regimens for patients with myelofibrosis, which were presented at the European Hematology Association (EHA) 2021 meeting.
Over the past decade there has been a vast increase in the number of clinical trials taking place in the field of myeloproliferative neoplasms (MPNs), with many trials investigating the potential benefits of novel JAK inhibitors both as monotherapy and in combination with other drugs, such as Bcl-2, Bcl-xL or BET inhibitors. More recently, next-generation sequencing has led to the identification of further mutations associated with MPNs, which may provide alternative therapeutic targets. In particular, the telomerase inhibitor imetelstat and the MDM2 inhibitor KRT-232, have demonstrated potential benefits for patients with myelofibrosis, whilst the tyrosine kinase inhibitor avapritinib recently received FDA approval for the treatment of advanced systemic mastocytosis.
In this roundtable discussion, leading MPN experts Ruben Mesa, MD, from the UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, and Naveen Pemmaraju, MD, of The University of Texas MD Anderson Cancer Center, review the top highlights from the 2021 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) meetings, including data on novel JAK inhibitors and combination regimens, therapies for rarer MPNs and updates from ongoing Phase III trials of key treatments.
Over the last years, the chronic lymphocytic leukemia (CLL) field has seen significant growth in new drugs and new treatment combinations. One emergent strategy is fixed-duration therapy, which combines two or more agents for a set timeframe. Fixed-duration therapy is an appealing option for different reasons, including shorter treatment times and lower costs. Ongoing clinical trials investigating fixed-duration therapy combinations, such as ibrutinib-venetoclax, will help determine the best drug combination as well as the patient populations that will benefit the most. Another increasingly important topic in the CLL field is the optimal treatment selection and sequencing of therapies in the era of targeted therapies.
In this exclusive podcast, Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, and Jacqueline Barrientos, MD, MS, Feinstein Institute for Medical Research, Manhasset, NY, discuss some of the latest updates in CLL treatment presented at the European Hematology Association (EHA) Congress 2021.
The treatment and management of multiple myeloma has evolved drastically over the last ten years with the introduction of many novel drug classes and therapies, resulting in notable improvements in overall survival. However, many patients remain relapsed or refractory and thus clinical trials of novel agents and combinations are key to improving the outcomes of high-risk subgroups. In particular, there has been a rapid increase in the number of immunotherapies being trialled for myeloma patients, including monoclonal antibody and chimeric antigen receptor T-cell (CAR-T) therapies.
In this podcast, Saad Usmani, MD, MBBS, MBA, from the Levine Cancer Institute and Atrium Health, Charlotte, NC, Maria-Victoria Mateos, MD, PhD, from the University of Salamanca, Salamanca, Spain, Enrique M. Ocio, MD, PhD, from the Marqués de Valdecilla University Hospital, Santander, Spain, Amrita Krishnan, MD, from City of Hope, Duarte, CA, and Evangelos Terpos, MD, PhD, from the National and Kapodistrian University of Athens, Athens, Greece, share key updates on clinical trials of novel therapies and regimens for the treatment of multiple myeloma, as presented at this year’s Congress of the European Hematology Association (EHA 2021).
There are several forms of acute lymphoblastic leukemia (ALL), with B-cell ALL being the most common (~75% of cases). A range of treatments are available for ALL, including chemotherapy, radiation therapy, and stem cell transplantation. Chimeric antigen receptor T-cell (CAR-T) therapy is a novel cellular therapy that has demonstrated potential for treating other forms of leukemia, such as B-cell non-Hodgkin lymphoma and multiple myeloma.
In this podcast, Reuben Benjamin, MBBS, FRCPath, PhD, from King's College Hospital, London, UK, Cameron Turtle, MBBS, PhD, FRACP, FRCPA, from the Fred Hutchinson Cancer Research Center, Seattle, WA, Claire Roddie, MD, PhD, from University College London, London, UK, Nirali Shah, MD, from the National Cancer Institute, Bethesda, MD, and Bianca Santomasso, MD, PhD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discuss the latest updates and future directions for the use of CAR-T therapy in the treatment of ALL.
During the COVID-19 pandemic, myeloma support and advocacy groups were forced to adapt to a new way of working in order to continue helping patients with myeloma and improving their quality of life. The COVID-19 pandemic has changed the way that patients with myeloma interact with their doctors, with phone and video appointments filling in for face-to-face appointments, as well as impacting on the role of nurses. Furthermore, the emotional burden of lockdowns and increased risk of severe COVID-19 infection for patients with hematological malignancies has made the role of myeloma nurses and advocacy groups more important than ever.
In this VJSession, chaired by leading myeloma expert Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, myeloma nurse Sarah Henshaw, BSc, MSc, and patient advocates Jack Aiello, Cindy Chmielewski and Jim Omel, MD, discuss myeloma from the patient’s perspective, highlighting challenges during the pandemic and the role of the patient advocate.
Over the past ten years, the approval of several new and effective therapies for multiple myeloma has significantly improved overall survival outcomes. The introduction of novel therapies has led to high levels of complete response, and many novel techniques are now being explored for the assessment of the depth of response, one of the most effective thus far being measurable residual disease (MRD). MRD describes a small number of cancer cells which remain after treatment but can only be detected by highly sensitive tests. MRD negativity has been demonstrated to be predictive of longer progression-free survival in a number of studies.
In this podcast, Bruno Paiva, PhD, of the University of Navarra in Pamplona, Spain, Noemi Puig, MD, PhD, of the University Hospital Salamanca in Spain, and Benjamin Derman, MD, of the University of Chicago in IL, discuss key research, presented at this year’s Congress of the European Hematology Association (EHA 2021), investigating the role of MRD in the management of multiple myeloma.
Chronic lymphocytic leukemia (CLL) is slow to develop and can be hard to treat as patients relapse or become refractory to currently available therapies. Chimeric antigen receptor T-cell (CAR-T) therapy is a novel type of treatment which is currently being explored for several forms of hematological cancer, with FDA approvals of CAR-T therapies for acute lymphoblastic leukemia and diffuse large B-cell lymphoma already in place. Recent trials, such as the TRANSCEND CLL004 trial, have reported promising data on the effectiveness of CAR-T in treating patients with CLL.
In this podcast, Jordan Gauthier, MD, MSc, from the Fred Hutchinson Cancer Research Center, WA, Tanya Siddiqi, MD, from the City of Hope National Medical Center, CA, and David Porter, MD, from the Abramson Cancer Center, PA, report on the latest results from clinical trials and discuss at what point we can consider the idea of curing CLL with CAR-T therapy.
Age is an important prognostic factor in multiple myeloma, with patients aged over 75 years showing inferior outcomes when compared to younger patients. Several factors play into the poor survival observed, including a higher incidence of severe disease, and high rates of comorbid conditions and functional impairment. However, the elderly population is heterogeneous, ranging from fit and active to frail and dependent. Thus, caring for older adults with myeloma is complex, with many patient factors influencing outcomes. The clinical approach in this patient population must be modified to account for comorbidities and the likelihood of higher treatment-related toxicity. The introduction of proteasome inhibitors in the last 20 years was a huge step to improving survival in elderly patients. These advancements have continued, with ongoing investigations into optimal PI-based combinations and other novel agents.
In this Post-COMy 2021 Myeloma Session, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France; Thierry Facon, MD, Lille University Hospital, Lille, France; and Alessandra Larocca, MD, PhD, of the University Hospital Città della Salute e della Scienza, Torino, Italy, discuss the latest in the treatment of elderly multiple myeloma. Featuring insights into how elderly myeloma treatment evolved to where we are today, frailty assessment, the challenges associated with the extremes of the frailty spectrum, and a look towards the future.
Advances in both the treatment landscape and the pathology of the disease have improved the outcome of children and adults with acute lymphoblastic leukemia (ALL). However, many challenges still remain, including the treatment of older patients with ALL, diagnosis of Philadelphia chromosome-like (Ph-like) ALL, a newly identified aggressive subtype, as well as the evolving role of hematopoietic stem cell transplantation.
In this exclusive podcast, VJHemOnc spoke with Selina Luger, MD, of the University of Pennsylvania, Philadelphia, PA, Sarah Tasian, MD, from The Children’s Hospital of Philadelphia, Philadelphia, PA and David Marks, MBBS, PhD, FRACP, FRCPath, of the University Hospitals Bristol NHS Foundation Trust, Bristol, UK, who discuss the challenges in managing older patients with ALL, diagnostic testing modalities for Ph-like ALL and post-allogeneic stem cell transplantation interventions to prevent and treat relapse in patients.
Myelodysplastic syndromes (MDS) are a heterogenous group of myeloid disorders characterized by the accumulation of dysplastic cells within the bone marrow, resulting in ineffective hematopoiesis and cytopenia. Around 30% of patients with MDS will progress to acute myeloid leukemia (AML). Hematopoietic stem cell transplantation (HSCT) currently represents the only curative option for MDS; however, novel strategies and therapies are under investigation, including personalized medicine approaches and immunotherapies.
In this VJSession, chaired by Amer Zeidan, MBBS, MHS, of the Yale University School of Medicine and Yale Cancer Center in New Haven, CT, Valeria Santini, MD, of the University of Florence in Italy and Eva Hellström-Lindberg of the Karolinska Institute in Sweden, discuss their experiences of breaking into the MDS field, share advice for women in science, and talk on the current state of the MDS space.
Acute myeloid leukemia (AML) is the most common type of leukemia in adults and is highly heterogenous. AML is typically treated with chemotherapy and allogeneic stem cell transplantation, however not all patients are eligible or able to tolerate these regimens, and many patients will experience relapse. Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated promising results in the treatment of B-cell lymphomas and is now being explored in AML, alongside other cellular therapies.
In this podcast, Saar Gill of the Perelman School of Medicines, PA, Richard Aplenc of the Children’s Hospital of Philadelphia, PA, Marion Subklewe of the LMU Hospital Munich in Germany, and Rizwan Romee of the Dana-Farber Cancer Institute, MA, discuss the latest data from clinical trials, comparing CAR-T therapy to other immunotherapeutic approaches, and outlining the potential role of CAR-NK cells in AML treatment.
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by the accumulation of dysplastic cells within the bone marrow, resulting in ineffective hematopoiesis and cytopenia. Patients typically have a median survival of 0.8 to 8.8 years. Around 30% of patients with MDS will progress to acute myeloid leukemia (AML). Hematopoietic stem cell transplantation (HSCT) currently represents the only curative option for MDS; however, novel strategies and therapies are under investigation, including personalized medicine approaches and immunotherapies.
In 2020, the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition (ASH 2020) was presented as an all-virtual event due to the COVID-19 pandemic. Despite this, the quality of data and presentations remained exceptionally high and it was not an event to be missed.
In this roundtable discussion, Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center in New Haven, CT, Uwe Platzbecker, MD, of the University of Leipzig in Leipzig, Germany, Andrew Brunner, MD, Massachusetts General Hospital in Boston, MA, and Jacqueline Garcia, MD, Dana-Farber Cancer Institute in Boston, MA, review the hottest topics in the treatment and management of MDS presented at the ASH 2020 Virtual Meeting.
The treatment of aggressive lymphomas such as diffuse large B-cell has seen dramatic changes, and with the advent of bispecific monoclonal antibodies, there is hope for a wider demographic of patients.
Due to the COVID-19 pandemic, the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition (ASH 2020) was held virtually – and it didn’t disappoint in the quality and breadth of data presented.
In this exclusive discussion leading experts Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK debate the latest in the treatment of lymphoma from the ASH 2020 virtual Annual Meeting and share how the new research and clinical updates can help improve patient management strategies in UK clinical practice.
The International Symposium on Hodgkin Lymphoma (ISHL) 2021 Hodgkin Lymphoma (HL) update gathered an international panel to discuss the most recent developments in HL, and provided a comprehensive update on current and emerging concepts. In this podcast, we spoke to Sven Borchmann, MD, of the University Hospital Cologne, Cologne, Germany, Paul Jan Bröckelmann, MD of the University Hospital of Cologne, Cologne, Germany, and Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, as they outline the latest thinking in HL, touching on the use of biomarkers in HL, first-line approaches as well as updates in relapsed/refractory disease.
The development of immunomodulatory agents and proteasome inhibitors alongside stem cell transplantation and chemotherapy has significantly improved the treatment options for patients with myeloma. Recently, B-cell maturation antigen (BCMA) has emerged as a promising target for myeloma treatment due to its selective expression in malignant plasma cells. Current work in this area focuses on determining the optimal combination of therapies, treatment strategies to overcome relapse, and clinical trials to aid the development of novel BCMA-targeted treatment modalities.
VJHemOnc is joined by Rakesh Popat, MBBS, MRCP, FRCPath, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, and Karthik Ramasamy, MD, MBBS, MRCP, FRCPath, PhD, of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, to discuss the latest research in myeloma presented at the American Society of Hematology (ASH) 2020 virtual annual meeting. These leading experts share their insights into emerging data on newly diagnosed myeloma, combination therapies in the relapsed setting, and novel BCMA-targeted myeloma therapies currently undergoing clinical trials such as CAR-T, BiTEs, and antibody-drug conjugates.
The European Group for Blood and Marrow Transplantation (EBMT) Trainee Committee was established in 2021 to address the needs of trainees in the field of bone marrow transplant and cellular therapy and provide advice and support for trainees. The group, composed of trainees, young investigators, and students, wants to encourage trainees to establish themselves within the EBMT community to help build a collaborative working relationship with other EBMT Committees and other associations and groups.
In this podcast, Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Claire Horgan, Paediatric Haematology Trainee, UK, and Yasmina Serroukh, MD, PhD, University of Montreal, Montreal, Canada, discuss the recent EBMT Trainee Committee, highlighting its goals and upcoming activities. Additionally, the speakers review the first ever special session, 'The EBMT for Trainees', that took place during the EBMT Annual Meeting 2021.
The most common form of amyloidosis, light-chain (AL) amyloidosis, results from abnormalities in plasma cells causing them to produce abnormal amyloid fibrils made up of immunoglobulin light chains. These insoluble fibrils deposit extracellularly and accumulate within organs such as the heart, kidneys, liver, spleen, nervous system, and digestive tract, disrupting their structure and impairing their function. Historically, successful treatments for amyloidosis have been anti-plasma cell chemotherapies that reduce the production of amyloidogenic light chains. More recently, monoclonal antibody treatments such as daratumumab, evaluated in the ANDROMEDA trial, have demonstrated efficacy against malignant plasma cells. Current investigations are also exploring the ability of monoclonal antibodies to target and eliminate amyloid from organs.
In this exclusive podcast, we are joined by Morie Gertz, MD, MACP, of the Mayo Clinic College of Medicine, Rochester, MN, Vaishali Sanchorawala, MD, of the Boston University Medical Center, Ashutosh Wechalekar, MBBS, MD, FRPC, FRCPath, DM, of the National Amyloidosis Centre, London, UK, and Raymond Comenzo, MD, of the Tufts New England Medical Center, Boston, MA. These experts discuss highlights from this year’s virtual American Society of Hematology (ASH) meeting and exposition, such as results from the ANDROMEDA study, the use of monoclonal antibodies, and unmet needs in AL amyloidosis diagnosis and awareness.
The 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held virtually this year and showcased the latest advances in the field of transplantation and cellular therapies.
VJHemOnc is joined by Christian Chabannon, MD, PhD, Institut Paoli Calmettes, Marseille, France, who chaired an insightful discussion on the main takeaways from the EBMT 2021 meeting, including trial updates in conditioning, novel approaches to managing graft-versus-host disease, the role of transplantation in rarer hematological malignancies and the latest news in immune effector cell therapies.
In this roundtable discussion, Prof. Chabannon is joined by Nico Gagelmann, MD, of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zinaida Perić, MD, PhD, of the University Hospital Centre Zagreb, School of Medicine, Zagreb, Croatia and Eolia Brissot, MD, of Saint-Antoine Hospital, Paris, France.
Acute myeloid leukemia (AML) is the most common type of adult leukemia, with over 19,500 new cases estimated to be diagnosed per year in the US alone. According to the NIH, 27.4% of people diagnosed with AML will survive for five years or more. AML is typically treated with a combination of cytarabine and anthracycline-based chemotherapy regimens, and allogeneic stem cell transplantation, in eligible patients. However, many patients will relapse after transplantation and many elderly patients cannot withstand intensive chemotherapy regimens. Thus, there remain unmet needs in the treatment of AML. The identification of mutations such as FLT3-ITD, NMP1 and CEBPA has improved risk-stratification and treatment optimization. Novel post-transplant maintenance therapies, as well as new approaches to transplantation are showing promise in improving outcomes for patients with AML.
In this podcast, Guillermo Sanz of the University Hospital La Fe, Valencia, Spain, Nico Gagelmann of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Mohamad Mohty of Saint-Antoine Hospital, Paris, France, and Farhad Ravandi, of the University of Texas MD Anderson Cancer Center, Houston, TX, share updates on their research in the field of AML which they presented at the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
The diagnosis and treatment of myelodysplastic syndromes (MDS) has moved on dramatically in the few three decades. From across the globe, pioneers in the recognition and understanding of MDS pulled together to collaborate and push forward this research laying the foundations of where we are today.
VJHemOnc were delighted to catch up with four of these pioneers to discuss their research – taking us from inception to future outlooks. Chaired by Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, this roundtable discussion included a prestigious panel in the world of MDS - Ghulam Mufti, OBE, DM, FRCP, FRCPath, King's College London, London, Peter Greenberg, MD, Stanford University Medical Center, Stanford, CA, Mario Cazzola, MD, University of Pavia, Italy and John M. Bennett, MD, University of Rochester Medical Center, Rochester, NY.
The armamentarium of therapeutic modalities in acute myeloid leukemia (AML) has taken several strides in the last few years as a result of a greater understanding of the genomic landscape disease as well as how resistance to conventional therapies can develop.
At the virtual 62nd American Society of Hematology 2020 Annual Meeting and Exposition (ASH 2020), we spoke with key opinion leaders in AML who shared the novel classes of drugs currently investigated in this disease area, which provide the field new opportunities for effective combination strategies.
In this podcast, Marina Konopleva, of the University of Texas MD Anderson Cancer Center, Houston, TX, David Sallman, of Moffitt Cancer Center, Tampa, FL, and Naval Daver, of the University of Texas MD Anderson Cancer Center, discuss some of the latest updates in AML presented at this year’s virtual American Society of Hematology (ASH) meeting.
The 3rd European CAR T-cell Meeting, organized by the European Society for Blood and Marrow Transplantation (EBMT), and the European Haematology Association (EHA), and shed light on the current and future indications of CAR T-cell therapies in hematological oncology. The nursing program highlighted key questions in the management of patients treated with cellular therapies including communication within multidisciplinary teams, the use of immune effector cells in solid tumors, the importance of treatment settings as well as survivorship considerations following CAR T-cell therapy.
In this roundtable discussion, Erik Aerts of the Hematology Nurses and Healthcare Professionals Group, Winterthur, Switzerland, leads an exciting discussion on key learnings and takeaways from the 3rd European CAR T-cell Meeting, and is joined by John Murray, of the Christie Hospital NHS Foundation Trust, Manchester, UK, Michelle Kenyon, of King’s College Hospital NHS Foundation Trust, London, UK, and Rose Ellard, of the Royal Marsden NHS Foundation Trust, London, UK.
Over the last decades, a deeper understanding of multiple myeloma's complex pathobiology has transformed the diagnosis, prognosis, and treatment paradigm, resulting in significant improvements in patient outcomes. Despite advances in treatment and outcomes, multiple myeloma is still considered an incurable disease. The management of newly diagnosed transplant-eligible patients and treatment approaches for relapsed/refractory myeloma remain hotly debated topics among the experts. The development of targeted and immune agents represents an important therapeutic strategy that can potentially translate into myeloma's eventual cure.
In this exclusive podcast, María-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, and Nina Shah, MD, University of California-San Francisco, San Francisco, CA, discuss the critical data presented at the ASH 2020 virtual Annual Meeting and how they might influence the treatment paradigm in myeloma.
Mechanistically, myeloproliferative neoplasms (MPNs), comprising primary myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), were a mystery for many decades. The breakthrough discovery of near-universal upregulation of the JAK-STAT signaling pathway as the driving force in MPNs triggered a wave of research that has drastically improved our understanding, and consequently broadened treatment options. Developing targeted therapies, particularly in settings of unmet need such as early-stage disease and second-line options, is an extensive area of investigation, with many novel classes in trials.
The annual meeting of the American Society of Hematology (ASH) consistently highlights biological and clinical updates in the MPNs field. The virtual 2020 ASH meeting was no exception, with emphases on significant genomic advances and emerging therapies.
In this latest exclusive, MPNs Session, we welcome Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX; Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX; and Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX. Our leading experts debate key updates in the treatment and management of MPNs following the ASH 2020 virtual meeting. In particular, they explore clonal evolution discoveries, as well as promising therapeutic strategies for PV, MF, ET and rarer MPNs.
During the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition, several abstracts provided important updates for the management of myelodysplastic syndromes (MDS), including clinical trial data for emerging therapeutic options for MDS.
In this podcast, we hear from three leading experts in MDS, who discuss the key updates presented at this year’s virtual ASH Annual Meeting. Uwe Platzbecker, MD, University Hospital Leipzig, Leipzig, Germany, shares the results from the ongoing Phase II IMerge trial of imetelstat for transfusion-dependent patients with lower-risk MDS. We are also joined by Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, who discusses the results of a Phase Ib study evaluating venetoclax in combination with azacitidine for patients with higher-risk MDS requiring treatment and not immediately undergoing transplantation at the time the study started. Additionally, Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, outlines the results of a Phase I trial investigating whether decitabine, a hypomethylating agent, increased the efficacy of CTLA-4 blockade with ipilimumab in patients with relapsed/refractory MDS or acute myeloid leukemia with or without prior allogeneic hematopoietic cell transplantation.
Improved understanding around the pathophysiology and heterogeneity of acute myeloid leukemia (AML) has led to a rapidly evolving treatment paradigm for this disease. New therapies and drug approvals have improved outcomes for patients, and in those not eligible for standard induction chemotherapy followed by transplantation, lower-intensity therapies have allowed patients to achieve disease control.
Due to the COVID-19 pandemic, the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition (ASH 2020) was held virtually – and it didn’t disappoint in the quality and breadth of data presented.
In this roundtable discussion, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, and Amir Fathi, MD, MPH, Massachusetts General Hospital Cancer Center, Boston, MA discuss and debate the key updates in the management of patients with AML presented ASH 2020.
The epidemiology, diagnosis and treatment of myelodysplastic syndromes (MDS) varies across the globe. In resource-limited countries, the diagnosis of MDS can be challenging – and databases with up-to-date information on the epidemiology of MDS is also not always available. Access to the latest technologies for diagnosis and treatment of patients can also be challenging. In this roundtable discussion, Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT chairs an excellent session discussing the epidemiology, diagnosis and treatment of MDS around the world. Dr Zeidan is joined by Anne Mwirigi, BSc, MBChB, MRCP, FRCPath, Aga Khan Hospital, Nairobi, Kenya, David Gomez-Almaguer, MD, Hospital Universitario UANL, Monterrey, Mexico, Mariana Guaraná, MD, Hemorio Institute, Rio de Janeiro, Brazil, Rishi Dhawan, MD, MRCP, DM, All India Institute of Medical Sciences, Delhi, India and Iman Aboudallé, MD, Naef K. Bassile Cancer Institute, American University of Beirut Medical Centre, Lebanon.
Amyloidosis is the name attributed to a group of diseases caused by the extracellular accumulation of amyloid, an abnormal, insoluble protein. Amyloid forms when protein misfolding transforms soluble precursor proteins into insoluble amyloid fibrils. Amyloid fibrils can disseminate systemically and deposition on organs causes disturbance of organ function. Deposition in cardiac tissue, kidneys and the central nervous system are the primary causes of patient deterioration. There are four main types of amyloidosis: AL (light chain), AA (inflammation), ATTR (hereditary and old age) and AB2M (caused by dialysis). AL amyloidosis is the most common type and is caused by clonal plasma cell dyscrasia. Treatment strategies depend on the type of amyloidosis. Recent treatment developments include novel chemotherapy agents and immunotherapies with monoclonal antibody therapies in particular showing promise.
In this podcast, Morie Gertz, MD, MACP, of the Mayo Clinic College of Medicine, Rochester, MN, Jason Valent, MD, from the Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, and Efstathios Kastritis, MD, of the University of Athens School of Medicine, Athens, Greece, discuss updates in the amyloidosis field presented at this year’s virtual American Society of Hematology (ASH) Annual Meeting and Exposition.
Chronic Lymphocytic Leukemia (CLL) is a B-cell malignancy, predominantly affecting the elderly, which is characterized by an accumulation of immunologically immature lymphocytes in the bone marrow, blood and lymphatic tissue. CLL is the most common type of leukemia. It develops very slowly and is generally incurable, with relapses often occurring after treatment. The past decade has seen significant growth in treatment options for CLL patients. While chemotherapy is still often used, numerous effective targeted agents are approved for use in CLL, both first-line and for relapsed/refractory disease. These include venetoclax, a BCL2 inhibitor approved for use in CLL in 2019; ibrutinib, a BTK inhibitor often used upfront; and monoclonal antibodies, including rituximab and obinutuzumab. The CLL field is currently seeing further exploration of targeted agents as well as trials of novel treatment combinations. In this exclusive podcast, Nitin Jain, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, and Anthony Mato, MD, and Meghan Thompson, MD, both from Memorial Sloan Kettering Cancer Center, New York, NY, discuss some of the latest updates in CLL treatment presented at this year’s virtual American Society of Hematology (ASH) meeting.
The field of multiple myeloma is rapidly evolving and can be credited to an increased understanding of the biology of the disease leading to an improvement in patients outcomes. Despite vast advances, the clinical management of patients with multiple myeloma remains challenging, namely resistance in relapsed patients as well as the identification of predictive and prognostic biomarkers.
In this podcast following the virtual annual American Society of Hematology (ASH) 2020 meeting, we hear from three leading experts in multiple myeloma, Niels van de Donk of the University Medical Center, Amsterdam, Netherlands, Yi Lin of Mayo Clinic, Rochester, MN and Maria-Victoria Mateos, of the University of Salamanca, Salamanca, Spain, who address the latest therapeutic approaches presented at ASH 2020 annual meeting.
Lymphoma is a group of malignant neoplasms of lymphocytes that progress in the lymphatic system. Generally, lymphomas are categorized into two groups: non-Hodgkin lymphoma and Hodgkin lymphoma. Depending on which type of lymphocyte is affected, NHL is classified into B-cell and T-cell NHL. The treatment landscape of B-cell NHL has evolved with the recent treatment developments, including chimeric antigen receptor (CAR) T-cell therapies. Axicabtagene ciloleucel (axi-cel), a CAR T-cell product, is currently being evaluated in patients with follicular lymphoma or marginal zone lymphoma in the ZUMA-5 trial. Additionally, lisocabtagene maraleucel (liso-cel) demonstrated promising clinical activity among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), according to the TRANSCEND study. One of the novel CAR T-cell products, AUTO3, which contains two independent CARs targeting CD19 and CD22, is being evaluated in patients with R/R diffuse large B-cell lymphoma.
In this fascinating podcast, Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Aravind Ramakrishnan, MD, Sarah Cannon Blood Cancer Center at St. David’s South Austin Medical Center, Austin, TX, discuss CAR T-cell therapy updates in the lymphoma field presented at the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition.
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of rare myeloid neoplasms characterized by the abnormal proliferation of hematopoietic stem cells within one or more terminal myeloid lineages. Recent advances in the field have drastically improved our understanding of the pathophysiology of MPNs, which have expanded the scope for potential novel therapies.
In this podcast, we are joined by Jyoti Nangalia, MBBChir, of Wellcome Sanger Institute, UK, Srdan Verstovsek, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, and Cem Akin, MD, of the University of Michigan, Ann Arbor, MI, to discuss pioneering data surrounding MPN pathogenesis and novel therapies presented at this year’s virtual American Society of Hematology (ASH) Annual Meeting and Exposition.
Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute myeloid leukemia. Patients with lower-risk MDS are defined as having a risk of very low, low, or intermediate disease according to the IPSS-R. The armamentarium of treatment approaches is broadening in the field of lower-risk MDS, however, greater advances in treatment strategies are required before we can confidently alter the natural course of disease in the majority of patients.
In this podcast, Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, chairs an insightful discussion on lower-risk MDS, focusing on diagnostic approaches and associated challenges, current management of disease as well as future novel therapeutic options for MDS patients. Dr Zeidan is joined by Valeria Santini, MD, of the University of Florence, Florence, Italy, Rami Komrokji, MD, of H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, and Olatoyosi Odenike, MD, of the University of Chicago, Chicago, IL.
Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are seen in 30% of all acute myeloid leukemia (AML) cases, most commonly involving the internal tandem duplication region (FLT3-ITD) which constitutively activate its kinase activity and thus, allows for leukemia cell proliferation and survival. A particularly poor prognosis is conferred by mutant FLT3, increasing relapse risk, and decreasing overall survival. For this reason, FLT3 genetic testing is advised at diagnosis, and the development of FLT3 inhibitors represent a significant research area over the past decade. Integration of these inhibitors, such as midostaurin and gilteritinib, have helped to improve outcomes of patients with AML but challenges remain, especially treatment resistance.
In this podcast, Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX chairs an insightful discussion on FLT3 mutated AML as part of the AML sessions, together with Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA; Jessica Altman, MD, Northwestern University, Chicago, IL; and Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY. They discuss novel treatment combinations for FLT3 mutated cancer, as well as treatment options for front-line and post-transplant maintenance settings, and mechanisms of resistance.
This year’s virtual International Workshop on Non-Hodgkin Lymphoma (iwNHL) highlighted key progress in our understanding of various non-Hodgkin lymphoma (NHL) subtypes, the role of the immune microenvironment, as well as evaluating novel therapeutic strategies in development for patients with NHL.
In this podcast, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of Barts Cancer Institute, London, UK, chairs a compelling discussion on key highlights from the iwNHL 2020 virtual meeting, including the next questions from the results of the KEYNOTE-204 trial in Hodgkin lymphoma, the significance of immunotherapy and the microenvironment, and an overview of exciting novel agents in NHL. Prof. Gribben is joined by Peter Borchmann, MD, of the University Hospital Cologne, Cologne, Germany, Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, and Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN.
Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute myeloid leukemia. With hematopoietic stem cell transplantation representing the only curative option for patients with MDS, the field has not seen the rapid evolution in treatments witnessed in other hematological malignancies.
In this podcast, Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, chairs a discussion evaluating issues pertaining to MDS, from clinical trial designs to the latest understanding of disease biology as well as future outlooks. Dr Zeidan is joined by Amy DeZern, MD, MHS, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Michael Savona, MD, of Vanderbilt University Medical Center, Nashville, TN, Mikkael Sekeres, MD, MS, of The Cleveland Clinic, Cleveland, OH and David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA.
The BCL-2 inhibitor venetoclax has been evaluated in many hematological malignancies, including acute myeloid leukemia (AML). More recently, emerging mechanisms of resistance and future directions of venetoclax in combination with hypomethylating agents and IDH inhibitors have been evaluated and data presented at EHA 2020, as well as SOHO 2020 has shown promising results in AML.
In this podcast, Naval Daver, of The University of Texas MD Anderson Cancer Center, Houston, TX, leads an exciting discussion alongside Courtney DiNardo and Marina Konopleva, also from The University of Texas MD Anderson Cancer Center, as well as Andrew Wei of Monash University, Melbourne, Australia, on the latest updates in the use of venetoclax-based regimens for the treatment of AML.
IDH mutations are present in 20% of acute myeloid leukemia (AML) patients and the use of IDH targeting agents has shown favorable clinical responses in AML, with ivosidenib and enasidenib (IDH1 and IDH2 inhibitors) being approved by the US F.D.A for relapsed/refractory AML patients.
In this podcast, Amir Fathi of Massachusetts General Hospital, Boston, MA, chairs a panel discussion evaluating the use of IDH inhibitors in AML and myelodysplastic syndromes, the potential of combination therapies using these agents, and the development of differentiation syndrome in AML. Dr Fathi is joined by Stephane De Botton of Gustave Roussy Institute, Villejuif, France, and Daniel Pollyea of the University of Colorado, Denver, CO.
The field of acute myeloid leukemia (AML) has seen rapid progression in the field of immuno-oncology which has led to vast improvements in patient outcomes. The annual Society of Hematological Oncology (SOHO) allowed great discussion of the translation of key data into clinical practice, including the state of the art in immunotherapy for AML.
In this podcast, Marion Subklewe of LMU Hospital Munich, Munich, Germany, leads a panel discussion evaluating checkpoint inhibitors, anti-CD47 therapy, BiTEs and CAR T-cell approaches in AML alongside Naval Daver of the University of Texas MD Anderson Center, Houston, TX, David Sallman of H. Lee Moffit Cancer Center, Tampa, FL and Amer Zeidan of Yale University and Yale Cancer Center, New Haven, CT.
Cell therapy involves the transplantation of viable cells into a patient in order to trigger a medicinal effect. CAR-T is a popular form of cell therapy, specifically immunotherapy, that can use a patient’s own altered immune cells to fight cancer.
In this podcast, Annalisa Ruggeri, MD, of IRCCS Ospedale Pediatrico Bambino Gesu, Noopur Raje, MD, of Massachusetts General Hospital, Matthew Frigault, MD, of Massachusetts General Hospital, and Maksim Mamonkin, PhD, of Baylor College of Medicine, discuss key updates and clinical trial results in the field of CAR-T and cellular therapies presented at EBMT 2020.
The Society of Hematologic Oncology (SOHO) 2020 Virtual Annual Meeting brought together global leading experts in hematological oncology who updated the community on the latest data and hot topics in the treatment and management of hematological malignancies.
The next questions session at SOHO 2020 illuminated important future considerations in many disease areas of hematological oncology as well as unmet needs in these patient populations.
In this podcast, we hear from Sagar Lonial, MD, FACP, of Winship Cancer Institute of Emory University, Atlanta, GA, Srdan Verstovsek, MD, PhD, and Loretta Nastoupil, MD of The University of Texas MD Anderson Cancer Center, Houston, TX, Amer Zeidan, MBBS, of Yale University and Yale Cancer Center, New Haven, CT, and finally John DiPersio, MD, PhD, of Washington University, St. Louis, MO, on the next questions in the treatment of patients with hematological malignancies.
Recent clinical trials studying novel therapeutic strategies to target chronic lymphocytic leukemia (CLL) have brought a spotlight to their potential as alternatives to traditional chemotherapy. Here we bring you an overview and discussion on the latest trial updates, including CLL12, CLL14, RESONATE, ASCEND, among others.
This podcast features Patrick Thornton from Beaumont Hospital, Dublin; Petra Langerbeins of the University of Cologne, Germany; Alessandra Tedeschi from Niguarda Cancer Center, Milan, Italy; Susan O’Brien of the University of California; Paolo Ghia of Università Vita-Salute San Raffaele, Milan, Italy; Othman Al-Sawaf of University Hospital Cologne, Germany; Arnon Kater from the University of Amsterdam; and Tanya Siddiqi of the City of Hope, California. The footage featured is from the European Hematology Association (EHA) 2019, held in Amsterdam, The Netherlands, and the International Conference on Malignant Lymphoma (ICML) 2019 in Lugano, Switzerland.
Myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell diseases characterized by the excessive production of one or more myeloid lineage with largely intact cellular differentiation. Recent advances in the field, such as the detection of new driver mutations and a better understanding of the molecular pathogenesis of MPNs, have revolutionized the diagnosis, classification and treatment of these hematological malignancies.
The First Texas MPN Workshop brought together medical experts in the field of MPNs to discuss the latest research and therapy options in development for MPNs. In this podcast, Ruben Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, Claire Harrison, MD, FRCP, FRCPath, Guy's and St Thomas' NHS Foundation Trust, London, UK and Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discuss the evolving management of MPNs, including learnings following COVID-19, mutations and molecular definitions of disease, interferon-based therapies, clinical trial updates and takeaways from the 2020 Texas MPN Workshop.
Acute myeloid leukemia (AML) is the most common type of acute leukemia among adults with almost 20,000 new cases reported in the US in 2020. With the identification of recurrent mutations and the development of novel agents, stratification has allowed for improvements in patient outcomes. In this podcast, Thomas Cluzeau, MD, PhD, of the Central University Hospital of Nice, Nice, France, Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, and Andrew Wei, MBBS, PhD, of Alfred Hospital and Monash University, Melbourne, Australia, discuss key updates in the AML field presented at EHA 2020.
Lymphoma encompasses a wide selection of cancers that progress in the lymphatic system. Broadly, two types of lymphoma exist, non-Hodgkin lymphoma which is the 7th most common cancer type in the US and UK, and conversely, Hodgkin lymphoma which constitutes 0.5-1% of all cancers reported in the US and UK. Treatment strategies depend on the type of lymphoma, as well as location and staging. Recent treatment developments include novel chemotherapy agents and immunotherapies including CAR T-cells and antibody-drug conjugates. In this podcast, Wendy Osborne, of Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, Peter Borchmann, from the University Hospital Cologne, Cologne, Germany, and Caron Jacobson, of the Dana-Farber Cancer Institute, Boston, MA, discuss updates in the lymphoma field presented at this year’s virtual EHA meeting.
Chronic lymphocytic leukemia (CLL) is a disorder characterized by morphologically mature but immunologically less mature lymphocytes, which accumulate in the bone marrow, lymphatic tissue and blood. CLL generally affects the older population and is incurable, however, several novel treatment approaches have developed to improve outcomes of patients with CLL and there is an increasing use of minimal residual disease (MRD) in disease monitoring. In this podcast, Lydia Scarfò, of Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, Othman Al-Sawaf of the University Hospital of Cologne, Cologne, Germany, and Tanya Siddiqi, from City of Hope, Duarte, CA discuss key developments in the treatment of CLL presented at this years EHA meeting.
It is an exciting time in terms of therapeutic progress for myeloproliferative neoplasms (MPN). In recent years, there have been significant advances in the understanding of MPNs, including underlying genetic changes that drive the development of MPNs. This has led to research focusing on targeted therapy and increased the availability of new treatment options.
In this podcast, Srdan Verstovsek, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, and Abdulraheem Yacoub, MD, of the University of Kansas Medical Center, Kansas City, MO, discuss key updates in the treatment and management of MPNs from this year’s European Hematology Association (EHA) 2020 congress.
A remarkable increase in the understanding of the pathogenesis of chronic lymphocytic leukemia (CLL) has led to the development of innovative therapies which has generated rapid progress in the management of CLL.
In this podcast, John Gribben of Barts Cancer Institute, London, UK, chairs an insightful discussion with Barbara Eichhorst of the University of Cologne, Cologne, Germany, Susan O’Brien of the University of California, Irvine, CA, and Matthew Davids of Dana-Farber Cancer Institute, Boston, MA, on the latest CLL updates from the recent Virtual ASCO and EHA 2020 Meetings. The speakers discuss frontline therapy for CLL, BTK inhibitors, novel combination therapies and the importance of measurable residual disease (MRD) assessment. Treatment sequencing and novel therapies, in particular CAR T-cell approaches were also discussed.
The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer...
The post The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation appeared first on VJHemOnc.
The acute myeloid leukemia (AML) field has witnessed rapid evolution of late, with exciting developments in strategies for the treatment...
The post The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML appeared first on VJHemOnc.
Acute lymphoblastic leukemia (ALL) is a malignant disorder of lymphoid progenitor cells affecting both adults and children. With a greater...
The post Key updates in ALL at EHA 2020 appeared first on VJHemOnc.
The multiple myeloma field is rapidly evolving, with exciting developments in strategies for the treatment of smoldering myeloma, relapsed/refractory (R/R)...
The post The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients appeared first on VJHemOnc.
Systemic mastocytosis (SM) is a rare hematological neoplasm. Advanced systemic mastocytosis can be sub-classified into either aggressive SM, SM with...
The post Systemic mastocytosis: current landscape, novel agents and COVID-19 appeared first on VJHemOnc.
Assessment of treatment efficacy in acute myeloid leukemia (AML) is highly relevant for further treatment stratification. In clinical trials, measurable...
The post MRD assessment in AML: incorporation into clinical practice appeared first on VJHemOnc.
The management of multiple myeloma presents many clinical challenges. The additional layer of complication COVID-19 places on patients and clinicians...
The post Myeloma management in the COVID-19 era appeared first on VJHemOnc.
Novel combinations work well for many patients suffering from chronic lymphocytic leukemia (CLL), but there is a subset of patients...
The post CAR-T in the CLL space appeared first on VJHemOnc.
In the majority of hematologic malignancies, induction treatment is given to achieve complete remission. In multiple myeloma, this has only been possible with the use of high-dose therapy plus autologous stem cell transplantation. Novel agents are changing the treatment landscape, with combinations of daratumumab, dexamethasone, thalidomide, bortezomib and lenalidomide increasing the rates of complete remission and partial response compared to VAD.
In this podcast, the endless possible combinations are discussed by Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital, Paris, France. Speaking from the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Prof. Mohty gives us his insight into induction therapy and also where we may be going next.
This is an exciting time in the acute leukemia field, with advances in both the treatment landscape and the pathology of the disease. This podcast features a recent discussion amongst acute leukemia experts from the International Workshop on Acute Leukemias (iwAL) 2019 conference held in Barcelona, Spain. In this podcast, Noelle Frey, MD , University of Pennsylvania, Philadelphia, PA; Bianca Santomasso, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY; and Wendy Stock, MD, of the University of Chicago Medicine, Chicago, IL, discuss a vast range of topics, including the improvement of patient outcomes, the use of CAR T-cell therapy and the importance of MRD in prognostics.
Precision medicine provides an array of benefits for the treatment of non-Hodgkin lymphoma patients, but it also has its challenges. Here, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of Barts Cancer Institute, London, UK, chairs a discussion with world-class lymphoma experts: Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, and Caron Jacobson, MD, from the Dana-Farber Cancer Institute, Boston, MA, on key updates from the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France. The group explores the use of CAR T-cell therapy, considering the hurdles and benefits, and discusses the realm of precision medicine in this field.
Determining measurable residual disease (MRD) status is undoubtedly proving to be an effective method of prognostication and measurement of response to novel therapies, hence justifying the mass of attention MRD testing is receiving in multiple myeloma (MM). From the Myeloma 2018 meeting, held in San Diego, CA, Gareth Morgan, MD, PhD, FRCP, FRCPath, of the UAMS Myeloma Institute, Little Rock, AR, chairs an insightful discussion with Jens Lohr, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, and Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, on the promising prospects of emerging, highly sensitive techniques for MRD testing. This podcast covers the enthralling discussion between the trio as they also tackle the question of how far away MRD testing is from prime time and routine clinical use in MM.